Estudios clínicos sobre nuestros tratamientos
Estudios médicos / estudios clínicos y literatura sobre las terapias que utilizamos en el Tratamiento de la depresión severa, ansiedades, trastorno obsesivo-compulsivo, trastornos neurológicos, Alzheimers y más. Estudios sobre la Ketaminoterapia para la depresión, la EMTr durante el embarazo y otros métodos terapéuticos como el EMDR, la realidad virtual, el Biofeedback HRV, el tDCS y el Neurofeedback.
Estudios clínicos sobre el uso de Ketamina medicinal
Akinosoglou K, Gogos A, Papageorgiou C, Angelopoulos E, Gogos C. Ketamine in COVID-19 patients: Thinking out of the box. J Med Virol. 2021 Jul;93(7):4069-4070. doi: 10.1002/jmv.26681. Epub 2020 Dec 1. PMID: 33215721; PMCID: PMC7753268.
Background. There are few studies on ketamine and its properties to work with addiction (alcohol, opioid, cannabis, and cocaine use disorder). The studies show that ketamine treatment can help reduce craving and support abstinence . Hypnotherapy is an evidence-based treatment gaining popularity for treating addiction, but not everybody can be hypnotized due to different levels of suggestibility. Our clinical practice has observed that people who are not highly hypnotizable, such as patients with obsessive-compulsive disorders, become more suggestible accompanied by our newly developed method called “Ketamine-Hypnosis package” (KHP). In this case report and study, we want to explore and evaluate the potential of KHP in working with addiction. Diagnostic and a qualitative content analysis should give profound insights into the treatment process and method.
Case Report. The subject is a 48-year-old male German Social Worker with treatment-resistant depression, suicidal thoughts, obsessive behavior, and several forms of addiction. The patient received a 10-day treatment at Instituto Dr. Scheib, with Diagnostic, rTMS, neurofeedback, and four sessions of KHP. Every Ketamine infusion remained with a standard dose of 0.5 mg/kg R-Ketamine for about 45 minutes.
Results. Primary outcome measures included change in depression as measured by the BDI-II with a reduction from 44, highly depressed, to a score of 3, no depression, and change of symptoms measured by the SCL-90 R that showed a clear reduction in almost every factor vs. baseline. The qualitative content analysis of the KHP sessions identified nine categories; Setting, Intervention, Body, Control, Feelings, Insights/Realizations, Addiction, Depression and Imagery. QEEG measurements before and after treatment showed a pattern of over-representation of slow brain activity with closed eyes, which can be observed in fluctuating concentration and volatile impulse control. Follow-Up Data with BDI-II one week after treatment showed factor 3 and 5 weeks after treatment factor 15.
Conclusions. The 10-day-treatment program improved numerous important treatment outcomes in one substance-dependent adult engaged in hypnotherapeutic modification, including promoting less substance abuse, diminishing craving, and reducing the risk of relapse. Further research is needed to replicate these promising results in a larger sample.
Opioid addiction in the United States currently presents a national crisis despite availability of different treatments. Prior findings suggest that both repetitive transcranial magnetic stimulation (rTMS) and subanesthetic dose of ketamine are efficacious in patients with opioid use disorders (OUD) when administered in isolation. However, their therapeutic value may be undermined by varying clinical responses that tend to dissipate with treatment cessation. There has been no study to date that has used a combination of both for OUD, and there are still many unanswered questions with respect to both. TIMBER (Trauma Interventions using Mindfulness Based Extinction and Reconsolidation of memories) therapy attempts to alter the expression of emotionally charged memories such as traumatic memories, and has been successfully tried in chronic post-traumatic stress disorder (PTSD) and in combination with memory-altering pharmacotherapy like ketamine infusion. By a combination of extinction and reconsolidation of memory approaches, TIMBER works to not over-flood and/or retraumatize as is seen in other treatment approaches. TIMBER involves a balanced combination of both the memory extinction and memory reconsolidation approaches (rather than extinction-only approaches) which explains its superior efficacy in PTSD and benefit in substance use disorders.
Opioid addiction in the United States (US) currently presents a national crisis despite availability of different treatments. Over 2.1 million people were diagnosed with opioid use disorder (OUD) in 2016 . Prior findings suggest that both repetitive transcranial magnetic stimulation (rTMS) and subanesthetic dose of ketamine are efficacious in patients with OUD when administered in isolation [1-4]. However, their therapeutic value may be undermined by varying clinical responses that tend to dissipate with treatment cessation. There has been no study to date that has used a combination of both for OUD, and there are still many unanswered questions with respect to both. Trauma Interventions using Mindfulness Based Extinction and Reconsolidation of memories (TIMBER) attempts to alter the expression of emotionally charged memories such as traumatic memories, and has been successfully tried in chronic post-traumatic stress disorder (PTSD) alone, or in combination with memory-altering pharmacotherapy like ketamine infusion [5-7]. By a combination of extinction and re-consolidation of memory approaches, TIMBER works to not over-flood and/or re-traumatize as is seen in other treatment approaches. At the present time, TIMBER has been shown to be efficacious in targeting trauma memories and their expressions in PTSD patients .
TIMBER uses all eight limbs of Yoga including the focused attention meditation and mindfulness meditation, the five-factor model of trauma or addiction experience, and integrates the principles of cognitive behavioral therapy (CBT) (mindfulness-based graded exposure therapy: MB-GET) with the neurobiology of emotionally charged traumatic or addiction memories. With respect to applying the translational model of TIMBER for drug addiction, the key steps are:
1. Inducing a mindful state (calm, alert but non-reactive) by use of a standardized meditation protocol (StaMP).
2. Creating drug-cues evoked controlled arousal response using a scripted brief narrative of the addiction experience by using the Buddha’s Five Factor Model (thoughts, feelings, memories, sensations/perceptions, and urges/impulses related to the addiction experience).
3. Using the mindfulness-based graded exposure therapy (MB-GET) and the TIMBER methods to decrease the arousal responses.
4. Using the already created mindful state to cognitively reprocess and reappraise the drug-related emotionally charged memories so that the drug-related emotionally charged memories are extinguished and de-conditioned from the cues and re-consolidated/updated as new memories.
TIMBER involves a balanced combination of both the memory extinction and memory reconsolidation approaches (rather than extinction only approaches) which likely explains its superior efficacies in PTSD and possibly in our future studies on drug addiction as well. The case series presented here is the extended application of the proof of concept model of TIMBER in three patients with chronic OUD.
Materials & Methods
The study is an open-label proof of concept study designed to test the feasibility and efficacy of ketamine, rTMS, and TIMBER in patients with OUD. The study included three patients all with a diagnosis of OUD. The primary outcome measure was percent reduction in cravings using the opiate use craving scale from baseline to the fifth rTMS session.
The following interventions were used:
1. Ketamine was given as a single infusion of 0.75 mg/kg weight-based dose capped at 745 mg total, administered over a 45 minute period. A one week washout period followed prior to the start of rTMS.
2. rTMS was performed for five sessions of 10 Hz and 3000 stimulation pulses applied to the right dorsolateral pre-frontal cortex (DLPFC) over one to two weeks.
3. Five sessions of TIMBER mindfulness-based therapy was carried out during the same two weeks period that rTMS was performed.
4. Home practice was then carried out two times daily with additional sessions on an as-needed basis whenever cravings were present.
Cravings were measured using the Opiate Craving Scale. Arousal responses were measured by a multi-system biofeedback bundle that comprised of real-time electroencephalogram (EEG), heart rate variability, and breath response pattern guided focused attention and mindfulness meditation practice (three minutes before rTMS, 21 minutes during, and three minutes after administration of rTMS).
In our open-label pilot study sample that consisted of three subjects with opiate use disorder (two with heroin use disorder and one with oxycodone use disorder), the participants rated their craving on the Opiate Craving Scale (OCS: scores range 0-30), five minutes before and five minutes after the rTMS stimulation . They rated their level of mindfulness pre-infusion baseline and after completing five sessions of TMS+mindfulness using the Assessment Scale for Mindfulness Interventions (ASMI) [6,7].
In these three subjects, at baseline, the mean OCS was 23.6 (SD 4.2), which indicates a high level. The OCS reduced to 8.2 (SD 2.7) after five sessions of TMS and mindfulness. Similarly, at baseline, their mean ASMI was 28.45 (SD 9.61). After five sessions of TMS and mindfulness, the mean ASMI was 49. 67 (SD 7.72) indicating a significant increase in mindfulness (Table 1).
Collectively all of these therapeutic interventions show promise as individual treatments for maintenance of abstinence in OUD, particularly improvement in cravings and increased motivation to quit. Significant long-term improvements in complete abstinence have been demonstrated with the use of ketamine following extended inpatient treatment [3,4], and ketamine reduced physiological response during opioid withdrawal . However, these studies on the use of ketamine are limited by their use of low-dose ketamine as the comparison group rather than a true placebo. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation technique currently approved for major depressive disorder. rTMS is currently being pursued as a treatment for substance use disorder. Preliminary data looking at treatment with rTMS to the dorsolateral pre-frontal cortex (DLPFC) has shown reduction in cravings in alcohol, cocaine, and nicotine use disorders . Single session rTMS studies have demonstrated that applying excitatory rTMS to the DLPFC can decrease cue-induced craving in nicotine, cocaine, and alcohol use disordered populations. The mechanism of rTMS success in treating addiction is thought to involve increased dopamine function in the shell region of the nucleus accumbuns .
Single session studies have only found small temporary reductions in craving, however more frequent sessions could lead to longer durations and greater reductions in cravings. The largest such clinical trial (n=130 smokers) demonstrated that 13 sessions of DLPFC rTMS resulted in six month tobacco abstinence rates of 33% . Trauma memories lay at the core of the pathogenesis of PTSD. TIMBER therapy attempts to alter the expression of emotionally charged memories such as traumatic memories, and has been successfully tried in chronic PTSD alone or in combination with memory altering pharmacotherapy like ketamine infusion [5,7]. There are many similarities between the emotionally charged memories common in PTSD, and the emotionally charged memories associated with addiction. Exposure to environmental cues such as people, places, or drug paraphernalia lead to a state of arousal and strong emotional response that often results in relapse for patients attempting to maintain sobriety. The use of mindfulness-based graded exposure therapy (MB-GET) and the TIMBER methods to decrease the arousal responses will extinguish drug-related emotionally charged memories while replacing them with new more adaptive memories. TIMBER aims to restructure cognitions and emotions, which prevents reactivity of the underlying memories in trauma .
A number of important questions remain. It is unclear how each of these modalities will function in combination and in comparison to a true placebo group. It is unclear what role baseline levels of desire to quit, motivation for treatment, and prior periods of abstinence have on the achievement and maintenance of abstinence. The groups chosen for the ketamine studies were treatment-seeking and completed three months of residential treatment prior to treatment with ketamine infusion [3,4]. The abstinence rates at one- and two-year follow-up for ketamine are promising; unique genetic and socioeconomic factors must be considered [3,4]. To date there is limited work examining the effect of rTMS on craving in OUD. However, preliminary data indicates significant possibility of reduced craving with multiple sessions of rTMS. While TIMBER methods have been successfully used to treat PTSD, this method has yet to be applied to substance use disorders on a mass scale. TIMBER involves a balanced combination of both the memory extinction and memory reconsolidation approaches (rather than extinction only approaches) and has possible implications for substance use disorder.
Combination therapy with ketamine, rTMS and TIMBER is feasible in patients with OUD. Although an open-label proof of concept study, the data suggests that the combination therapy reduces craving, promotes abstinence, and reduces the amount used in patients with OUD. Combination therapy allows patients to be actively involved in their care by engaging in meditative therapy-based techniques that directly result in a calmer state of mind. This protocol allows concurrent implementation of three individually effective interventions in combination for a compounding synergistic effect.
Link to publication: https://europepmc.org/article/pmc/pmc7779150#free-full-text
Available online 11 December 2020
Authors: Jiaqi Xiong1 Orly Lipsitz3 David Chen-Li3 Joshua D.Rosenblat123 Nelson B.Rodrigues3 Isabelle Carvalho3 Leanna M.W. Lui3 Hartej Gill34 Flora Narsi3 Rodrigo B. Mansur3 Yena Lee3 Roger S. McIntyre1234
• Single-dose intravenous ketamine/intranasal esketamine has rapid and robust acute effects in reducing suicidal ideation (SI).
• Future high-quality research on the anti-SI efficacy of alternative administration routes (i.e. intramuscular, subcutaneous, oral/sublingual) and formulations of ketamine is needed.
• Dosage, routes of administration, and formulations are factors to be considered for optimizing SI treatment using ketamine.
The efficacy of ketamine in reducing suicidal ideation (SI) has been previously reported. We aimed to evaluate acute anti-SI effects of single-dose ketamine in different formulations/routes of administration by pooling results from randomized controlled trials (RCTs). A systematic search was conducted on Cochrane, Embase, Medline, and PubMed from inception to July 1st, 2020. Studies were selected based on pre-determined eligibility criteria. Effect sizes of different formulations/routes at various time points were computed using random-effects models. With data from nine eligible RCTs (n=197), the pooled effect size for anti-SI effects at 24-hour time point was 1.035 (N=6, CI: 0.793 to 1.277, p<0.001) for intravenous (IV) racemic ketamine and 1.309 (N=1, CI: 0.857 to 1.761, p<0.001) for intranasal (IN) esketamine. An additional five RCTs were available for qualitative analysis. RCTs were identified for oral/sublingual ketamine for depression, however, none of these trials reported anti-SI effects preventing quantitative analysis for these routes of delivery. No RCTs for intramuscular (IM) ketamine were identified. The findings suggest that single-dose IV ketamine/IN esketamine is associated with robust reductions in suicidal thoughts at 2-hour, 4-hour, and 24-hour post-intervention. In addition, future studies on IM/oral/sublingual ketamine and comparative studies are warranted to evaluate the anti-SI efficacy of distinct formulations and routes of administration.
Volume 105, 8 March 2021, 110126
Authors: Orly Lipsitzab Roger S.McIntyreabcd Nelson B.Rodriguesab Tyler S. Kasterdh Danielle S. Chaab Elisa Brietzkejk Hartej Gillab Flora Nasria Kangguang Linef Mehala Subramaniapillaiab Kevin Kratiukb Kayla Teopizb Leanna M.W. Luia Yena Leeab Roger Hog Margarita Shekotikhinaabi Rodrigo B. Mansurad Joshua D. Rosenblatabcd
• Early symptom improvement was associated with greater antidepressant effects following four ketamine infusions.
• ~40% of individuals with early improvement responded to the full treatment course versus 14–19% in non-early improvers.
• 58% of individuals who did not experience early improvement experienced a partial to full response after the fourth infusion.
Early symptomatic improvement with monoamine-based antidepressants is predictive of treatment response. The objective of this study was to determine if early symptomatic improvements with intravenous (IV) ketamine predicted treatment response to an acute course of four infusions.
134 adults with treatment resistant depression (TRD) received four ketamine infusions over one to two weeks. Depressive symptoms were measured using the Quick Inventory for Depressive Symptomatology Self-Report16 (QIDS-SR16) at baseline and post-infusions 1, 2, 3, and 4. Early improvement was defined as ≥20% reduction in QIDS-SR16 scores after the first or second infusion. Linear models were used to determine whether early improvement was associated with post-infusion 4 QIDS-SR16 scores after controlling for baseline characteristics.
Early improvement post-infusion 1 (β = −3.52, 95% BCa CI [−5.40, −1.78]) and 2 (β = −3.16, 95% BCa CI [−5.75, −1.59]) both significantly predicted QIDS-SR16scores post-infusion 4. Early improvers had significantly lower QIDS-SR16 scores at post-infusion 4 (post-infusion 1 improvers: M = 9.8, SD = 4.5; post-infusion 2 improvers: M = 10.6, SD = 5.7) compared to non-early improvers (post-infusion 1 non-improvers: M = 13.7, SD = 5.8; post-infusion 2 non-improvers: M = 14.1, SD = 5.3) when controlling for baseline characteristics. The majority (58%) of individuals who did not improve post-infusions 1 or 2 still experienced an antidepressant response or partial response (≥20% reduction in QIDS-SR16) post-infusion 4.
This is a post-hoc analysis of an open-label study.
Early improvement was associated with greater antidepressant effects following a course of four ketamine infusions. However, individuals who did not show early improvements still had a high likelihood of experiencing clinically significant symptom reduction after the fourth infusion, suggesting that completing four infusions, regardless of early symptom changes, is appropriate and merited.
Steven R.D. Best a,*, Dan G. Pavel b, Natalie Haustrup c
a The Neuroscience Center, Deerfield, IL, USA
b PathFinder, Brain SPECT Imaging, Deerfield, IL, USA
c Haustrup Scientific Consulting, Cambridge, UK
A R T I C L E I N F O
Keywords: Psychiatry, Neurology, TMS, Depression, Ketamine, Comorbidity, Biomarker, Combination
A B S T R A C T
Background: Both transcranial magnetic stimulation (TMS) and infused ketamine are recognized treatments for patients suffering from major depressive disorder (MDD). A novel therapy named combination TMS with ketamine (CTK) is introduced. This retrospective review examined the safety and clinical benefits of CTK in patients suffering from treatment-resistant depression (TRD) during the routine practice of psychiatry in a private clinic.
Methods: TRD patients (N . 28) received a coincident application of high-output TMS (30 minutes) with biomarker-determined ketamine infusions (20 minutes). Frequency of treatment was dependent on patient responsiveness (10–30 sessions). Clinical global impression (CGI) data was collected pre- and post-treatment and then two years later.
Results: The mean reduction in CGI severity for the patient group following CTK was 4.46 0.54 at a 99% confidence interval and was deemed statistically significant using a paired t-test (α . 0.01, t . 22.81 p < 0.0001).
This reduction was sustained for two years following treatment completion and this remission was deemed statistically significant by a second paired t-test (α . 0.01, t . 27.36, p < 0.0001).
Limitations: Retrospective review of a limited number of patients undergoing CTK in a clinical practice.
Conclusions: This clinical review indicated that CTK is an effective, long-term therapy (after two years) and can be used for TRD patients. The coincident administration of ketamine allowed for higher TMS intensities than otherwise would be tolerated by patients. Further studies for optimization of CTK are warranted.
Treatment-resistant depression refers to a major depressive disorder (MDD) with a lack of clinically meaningful improvement to an appropriate course (adequate dose over 6–8 weeks) of at least two antidepressants from different pharmacological classes, prescribed for adequate duration, with adequate affirmation of treatment adherence (Little, 2009; EMA Guidelines, 2013). It is estimated that between 15% and 33% of patients will not respond to multiple interventions and therefore be classed as suffering from treatment-resistant depression (Little, 2009).
The sequenced treatment alternatives to relieve depression (STAR*D) trial explored the effectiveness of alternative treatments for treatment-resistant depression patients and predicted that only a third of the 20 million Americans suffering from MDD would achieve remission (Warden et al., 2007). Continued depressive symptoms have been linked to social issues, a greater risk of suicide and mortality and ultimately results in increased health-care costs (Lepine and Briley, 2011; Kellar et al., 2016).
The cause of such depressive disorders remains unclear. However, it is commonly agreed that it relates to a system disorder affecting pathways between cortical, subcortical and limbic sites, along with the neurotransmitter and molecular mediators (Mayberg et al., 2005). Patients with unipolar depression have been shown to have prefrontal abnormalities, predominantly on the left and decreased neuronal activities in the dorsolateral prefrontal cortex (PFC) regions, as well as in the rostral anterior cingulate cortex (ACC) areas, closely connected to the dorsolateral PFC (Baeken and De Raedt, 2011).
Research has shown a strong negative correlation between the ACC
* Corresponding author.
E-mail address: firstname.lastname@example.org (S.R.D. Best).
Contents lists available at ScienceDirect
journal homepage: www.heliyon.com
Received 28 February 2019; Received in revised form 31 May 2019; Accepted 26 July 2019
2405-8440/© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Jerome H Taylor,
- Angeli Landeros-Weisenberger,
- Catherine Coughlin,
- Jilian Mulqueen,
- Jessica A Johnson,
- Daniel Gabriel,
- Margot O Reed,
- Ewgeni Jakubovski&
- Michael H Bloch
Many patients with social anxiety disorder (SAD) experience inadequate symptom relief from available treatments. Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared the effects between intravenous ketamine (0.5 mg/kg over 40 min) and placebo (normal saline) on social phobia symptoms. Ketamine and placebo infusions were administered in a random order with a 28-day washout period between infusions. Ratings of anxiety were assessed 3-h post-infusion and followed for 14 days. We used linear mixed models to assess the impact of ketamine and placebo on anxiety symptoms. Outcomes were blinded ratings on the Liebowitz Social Anxiety Scale (LSAS) and self-reported anxiety on a visual analog scale (VAS-Anxiety). We also used the Wilcoxon signed-rank test to compare the proportion of treatment responders. Based on prior studies, we defined response as a greater than 35% LSAS reduction and 50% VAS-Anxiety reduction. We found ketamine resulted in a significantly greater reduction in anxiety relative to placebo on the LSAS (Time × Treatment: F9,115=2.6, p=0.01) but not the VAS-Anxiety (Time × Treatment: F10,141=0.4, p=0.95). Participants were significantly more likely to exhibit a treatment response after ketamine infusion relative to placebo in the first 2 weeks following infusion measured on the LSAS (33.33% response ketamine vs0% response placebo, Wilcoxon signed-rank test z=2.24, p=0.025) and VAS (88.89% response ketamine vs 52.94% response placebo, Wilcoxon signed-rank test z=2.12, p=0.034). In conclusion, this proof-of-concept trial provides initial evidence that ketamine may be effective in reducing anxiety.
Paul Glue, Shona Neehoff, Amandine Sabadel, …
First Published September 17, 2019 Research Article Find in PubMed
We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social anxiety disorders.
The purpose of this study was to replicate our earlier report about ketamine‘s anxiolytic activity, using a more robust study design.
This was a double-blind, psychoactive-controlled ascending dose study in 12 patients with treatment-resistant generalized anxiety and social anxiety disorders who were not currently depressed. Ascending doses of ketamine (0.25, 0.5, 1 mg/kg) were administered at weekly intervals, and midazolam 0.01 mg/kg, the control, was randomly inserted into the ketamine dose sequence. Assessments included ratings of anxiety and dissociation, safety and tolerability, and blood samples for ketamine pharmacokinetics and BDNF concentrations.
Improvements in anxiety ratings occurred within an hour of ketamine dosing, and persisted for up to 1 week. A dose-response profile was noted for anxiolytic effects, dissociative side effects, and changes in blood pressure and heart rate after ketamine dosing. Midazolam had minor brief effects on anxiety ratings. Ketamine was safe and well tolerated. Ketamine pharmacokinetics were correlated with dissociation ratings. Serum BDNF concentrations declined over time and were similar for all treatments.
Ketamine may be a potential therapeutic option for patients with treatment-resistant generalized anxiety and social anxiety disorders.
Jennifer L. Phillips1,2, Sandhaya Norris1,2, Jeanne Talbot1,2, Taylor Hatchard1, Abigail Ortiz 1, Meagan Birmingham1, Olabisi Owoeye1,2, Lisa A. Batten1 and Pierre Blier1,2,3
Repeated administration of subanesthetic intravenous ketamine may prolong the rapid decrease in suicidal ideation (SI) elicited by single infusions. The purpose of this secondary analysis was to evaluate reduction in SI with a single ketamine infusion compared with an active control, and prolonged suppression of SI with repeated and maintenance infusions. Thirty-seven participants with treatment-resistant depression (TRD) and baseline SI first received a single ketamine infusion during a randomized, double-blind crossover with midazolam. Following relapse of depressive symptoms, participants received six open-label ketamine infusions administered thrice-weekly over 2 weeks. Antidepressant responders (≥50% decrease in Montgomery-Åsberg Depression Rating Scale [MADRS] scores) received four further open-label infusions administered once-weekly. Changes in SI were assessed with the suicide items on the MADRS (item 10, MADRS-SI) and the Quick Inventory of Depressive Symptomatology-Self Report (item 12, QIDS-SI). Linear mixed models revealed that compared with midazolam, a single ketamine infusion elicited larger reduction in SI (P = 0.01), with maximal effects measured at 7 days postinfusion (P < 0.001, Cohen’s d = 0.83). Participants had cumulative reductions in MADRS-SI scores with repeated infusions (P < 0.001), and no further change with maintenance infusions (P = 0.94). QIDS-SI results were consistent with MADRS-SI. Overall, 69% of participants had a complete alleviation of SI following repeated infusions. In TRD, single and repeated ketamine infusions resulted in decreases in SI which were maintained with once-weekly maintenance infusions. This study adds to the growing body of research suggesting ketamine as a possible novel treatment strategy for SI in mood disorders.
Neuropsychopharmacology (2019) 0:1–7; https://doi.org/10.1038/s41386-019-0570-x
Muris Humoa, Beyza Ayazgökab, Léa J.Beckera, Elisabeth Waltispergera, Tomi Rantamäkicd, Ipek Yalcina
Volume 100, 8 June 2020,
Chronic pain produces psychologic distress, which often leads to mood disorders such as depression. Co-existing chronic pain and depression pose a serious socio-economic burden and result in disability affecting millions of individuals, which urges the development of treatment strategies targeting this comorbidity. Ketamine, a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) receptor, is shown to be efficient in treating both pain and depression-related symptoms. However, the molecular characteristics of its role in chronic pain-induced depression remain largely unexplored. Hence, we studied the behavioral and molecular effects of a single systemic administration of ketamine (15 mg/kg, i.p.) on mechanical hypersensitivity and depressive-like consequences of chronic neuropathic pain. We showed that ketamine transiently alleviated mechanical hypersensitivity (lasting <24 h), while its antidepressant effect was observed even 72 h after administration. In addition, ketamine normalized the upregulated expression of the mitogen activated protein kinase (MAPK) phosphatase 1 (MKP-1) and the downregulated phosphorylation of extracellular signal-regulated kinase (pERK) in the anterior cingulate cortex (ACC) of mice displaying neuropathic pain-induced depressive-like behaviors. This effect of ketamine on the MKP-1 was first detected 30 min after the ketamine administration and persisted until up to 72 h. Altogether, these findings provide insight into the behavioral and molecular changes associated with single ketamine administration in the comorbidity of chronic pain and depression.
Aust N Z J Psychiatry. 2020 Jan;54(1):29-45. doi: 10.1177/0004867419883341. Epub 2019 Nov 15.
Ketamine may reduce suicidal ideation in treatment-resistant depression. But it is not known how quickly this occurs and how long it persists. We undertook a systematic review and meta-analysis to determine the short- and long-term effectiveness of ketamine for suicidality.
CENTRAL, EMBASE, Medline, and PsycINFO were searched until 12 December 2018. Randomised controlled trials of ketamine or esketamine reporting data on suicidal ideation, self-harm, attempted or completed suicide in adults diagnosed with any psychiatric disorder were included. Two reviewers independently extracted data, and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation tool. Standardised mean difference was used for continuous outcomes.
Twenty-five reports from 15 independent trials, with a total of 572 participants diagnosed with predominately affective disorders, were included. The evidence was rated moderate to low. In most trials, ketamine was administered at 0.5 mg/kg via a single intravenous infusion over a 30- to 45-minute period. Only a single trial of intranasal esketamine was identified. At 4 hours post-infusion, treatment with ketamine was associated with a significant reduction in suicidal ideation scores (standardised mean difference = -0.51, 95% confidence interval = [-1.00, -0.03]), which persisted until 72 hours post-infusion (time points between 12 and 24 hours: standardised mean difference = -0.63, 95% confidence interval = [-0.99, -0.26]; between 24 and 72 hours: standardised mean difference = -0.57, 95% confidence interval = [-0.99, -0.14]), but not thereafter. However, there was marked heterogeneity of results. In a single trial of esketamine, marginal effects on suicidal ideation were observed. In terms of actual suicidal behaviour, there were virtually no data on effects of ketamine or esketamine.
A single infusion of ketamine may have a short-term (up to 72 hours) beneficial impact on suicidal thoughts. While confirmation of these results in further trials is needed, they suggest possible use of ketamine to treat acute suicidality. Means of sustaining any anti-suicidal effect need to be found.
In the present article, we report on the case of a 23-year-old woman with a history of treatment-resistant depression who achieved significant symptom improvement with a novel treatment consisting of ketamine, a dissociative anesthetic, and external neuromodulation with transcranial magnetic stimulation (TMS). This case highlights the need for further investigation of treatments pairing external neuromodulation with dissociative anesthetics.
Despite advances in pharmacological treatment, approximately half of patients fail to achieve full remission, prompting researchers to look beyond conventional antidepressant medications . Recent research has examined transcranial magnetic stimulation (TMS and its variant rTMS), in which an electromagnetic stimulator positioned at the scalp induces a change in local and distant electric field conditions and may cause an associated depolarization of neurons . When used to stimulate the dorsolateral prefrontal cortex, rTMS has been associated with significant antidepressant effects , and is an FDA-approved treatment for depression. However, it is difficult to achieve remission with rTMS alone. A separate body of research has investigated intravenous ketamine, an N-methyl-D-aspartate (NMDA) antagonist [4–8]. In contrast to typical antidepressant medications that take effect within several weeks, ketamine provides relief within 2 h and lasts between four and seven days, after which relapse is common [4,5]. To date, little is known about the possible synergistic effects of combined rTMS/ketamine treatment for depression.
One study found that a factor underlying treatment resistance in depression is abnormal function in a thalamocortical circuit involving the anterior cingulate cortex (ACC), among other areas [9,11]. Accordingly, the first author hypothesized stimulating the ACC with TMS would restore normal functioning in the relevant circuit, thereby improving response to ketamine. We report on a depressed patient treated with a novel combined ketamine/TMS technique who showed substantial improvement in depression symptomatology at the end of treatment, and again at follow-up 483 days later. An IRB exemption was obtained from an independent accredited agency.
Case Report. Patient X is a 23-year-old woman who presented with a 9-year history of depression that did not respond to treatment with sertraline, buprorion, paroxetine, or stimulants. She also presented with attention deficit disorder that was treated with amphetamine from intake through follow-up. Her past history included diagnoses of anorexia nervosa and substance abuse (cocaine) that were in full remission at intake. Patient X was systematically assessed for psychopathology by an independent licensed psychologist at the outset of treatment. The primary assessment instruments were the Beck Depression Inventory-II (BDI-II) and the Personality Assessment Inventory (PAI). PAI subscale scores greater than 70 indicate clinically significant difficulties. Results of this assessment suggested that Patient X exhibited moderate levels of depression (BDI-II = 17, PAI DEP T = 84) consisting predominantly of depressed mood (PAI DEP-A T = 83), low self-esteem (PAI DEP-C T = 87), and suicidal ideation (PAI SUI T = 62). In addition, the initial assessment suggested significant difficulties in developing and maintaining a sense of life purpose and self-identity (PAI BOR-I T = 80), problematic alcohol use (PAI ALC = 66), and concentration difficulties (PAI SCZ-T T = 73). After this comprehensive assessment, Patient X’s mood was assessed during each treatment by the first author using a visual analog scale. In this measure, Patient X indicated where her mood fell along a continuum from “the worst I can imagine feeling” to “the best I can imagine feeling.”
Prior to beginning combined treatment, Patient X was given 2 days of rTMS pretreatment (four treatments per day of 30 min with 45 min of rest between treatments). Combined ketamine/TMS treatment began the following day and continued at weekly intervals for 13 weeks. Fifteen years of observational evidence from our clinic suggested that this duration produced clinically significant results. Combined treatment consisted of 40 min of 1 Hz continuous TMS with an intravenous ketamine infusion administered concurrent to and bracketed within the middle 30 min of TMS, resulting in 5 min of TMS pre- and postinfusion. The dosage of infused ketamine increased gradually from 30 mg at the first treatment to 100 mg at the last treatment. During combined treatment, the TMS head coil (manufactured by Neotonus) was positioned at the midline of the scalp to achieve maximal stimulation of the medial prefrontal area that overlays the anterior cingulate, a region implicated in depression . While direct stimulation of the anterior cingulate is not likely given its subcortical position and the limited electromagnetic field penetration of TMS coils , we hypothesized that indirect stimulation of the anterior cingulate via TMS applied to the overlaying scalp region would result in a beneficial effect.
Baseline brain scans were used to ensure accurate coil positioning at each treatment. TMS treatments were administered at 115% of motor threshold at 1 Hz continuous pulsation given that these settings were within safety guidelines and consistent with previous research. Using this method, we hypothesized that the dissociative effects of ketamine along with TMS activation of the anterior cingulate would help reestablish normal oscillatory rhythms in this region, leading to a decrease in depression symptoms.
After the treatment on week three, Patient X reported a substantial improvement in mood and energy levels. Patient X noted that these gains were maintained over the duration of treatment with some fluctuation in mood due to relationship difficulties. Soon after the last combined treatment, Patient X reported a nondepressed mood with increased motivation and diminished attention difficulties. Combined treatment was followed by regular psychiatric visits 1–2× /month for 14 months. Gains were generally maintained over this span, with Patient X reporting that she was able to begin graduate studies and sustain an intimate relationship. Four hundred and eighty three days after her initial assessment, Patient X was again systematically assessed for psychopathology by an independent licensed psychologist. Results showed substantial decreases in depression (BDI-II = 0, PAI DEP T = 41), suicidal ideation (PAI SUI T = 45), alcohol use (PAI ALC T = 49), and concentration difficulties (PAI SCZ T = 49), along with increased sense of self-purpose (PAI BOR-I T = 56).
Discussion. This case report adds to the literature on improving the efficacy of brain electromagnetic stimulation by administering pharmacological agents that modulate glutamatergic transmission. Whereas previous research suggests that rTMS is somewhat effective in treating depression , and that subanesthetic doses of ketamine are temporarily helpful with depression [5–9]; the present case report is the first to suggest that a combined ketamine/rTMS treatment may be a more efficacious treatment for refractory depression than either infused ketamine or rTMS alone. Future research should examine combined ketamine/TMS treatment in a randomized controlled trial.
Declaration of Interest
Dr. Best reports no biomedical financial interests or potential conflicts of interest. Brian Griffin reports no biomedical financial interests or potential conflicts of interest. The authors alone are responsible for the content and writing of this paper.
- Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351–4. [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
- Barker AT. An introduction to the basic principles of magnetic nerve stimulation. J Clin Neurophysiol 1991;8:26–37. [Google Scholar]
- Gross M, Nakamura L, Pascual‐Leone A, Fregni F. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. Acta Psychiatr Scand 2007;116(3):165–73. [Google Scholar]
- Deng ZD, Lisanby SH, Peterchev AV. Electric field depth–focality tradeoff in transcrancial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimul 2013;6(1):1–13. [Google Scholar]
- Diazgranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605–11. [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
- Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2012;74(4):250–6. [Google Scholar]
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856–64. [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
- Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939–46. [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
- Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526–33. [Google Scholar]
- Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45(5): 651–60. [Crossref], [PubMed], [Web of Science ®], [Google Scholar]
- LLínas RR, Ribary U, Jeanmond D, et al. Thalamocortical dysrhythmia: a neurological and neuropsychiatric syndrome characterized by magnetoencephalography. Proc Natl Acad Sci 1999;96(26):15222–7. [Google Scholar]
The fast-acting nasal spray esketamine, marketed as SpravatoTM, was recently approved by the Food and Drug Administration (FDA) to treat depression in individuals whose depression has been resistant to at least two medications. Structurally, esketamine is an enantiomer, or mirror image, of ketamine and works by a similar mechanism.1 The antidepressant response is evident within a few days of administration, unlike traditional antidepressants that often take weeks for the patient to feel any improvement in mood. This is particularly advantageous for patients who have suicidal thoughts and need quick resolution of depression symptoms.
While an old anesthetic drug, this new formulation has yet to be explored extensively through clinical studies in the pregnant and breastfeeding population. Interestingly, animal studies conducted don’t seem to produce promising results. A new study conducted in 2017 found that offspring of pregnant rats treated with ketamine had impaired learning and memory.2 Another study found that offspring of rats treated with ketamine during the second trimester had long-term neurocognitive dysfunction.3 A study in 2016 found that ketamine exposure during pregnancy in rats resulted in reduced development of certain brain regions in the offspring.4 Thus, at this time, ketamine’s effects in pregnancy are concerning and it is not recommended for use during pregnancy. Although the FDA has not assigned a pregnancy category to esketamine, the pharmaceutical provider suggests that SpravatoTM may cause fetal toxicity and should be avoided in pregnant and breastfeeding women.5
This is not to say that women shouldn’t seek treatment for depression during pregnancy, however. It is instead recommended that pregnant or potentially soon-to-be pregnant women turn to older antidepressants, such as select serotonin reuptake inhibitors (SSRIs). The more popular antidepressants used during pregnancy include sertraline, escitalopram, or fluoxetine.6 Paroxetine has been associated with an increased risk of cardiac defects in exposed infants with exposure in the 1st trimester.6 Bupropion is another alternative treatment for depression in pregnant mothers. Treatment should be initiated on a case-by-case basis depending on severity of symptoms and personal history. All of these aspects should be discussed with a physician before initiating therapy. Medication changes should ideally be made prior to pregnancy.6
Common antidepressants in pregnancy:
|Bupropion||Animal studies revealed no evidence of harm6|
|Citalopram||Possible SSRI withdrawal syndrome6|
|Esketamine||New to the market|
|Escitalopram||Possible SSRI withdrawal syndrome6|
|Fluoxetine||Possible SSRI withdrawal syndrome6|
|Paroxetine||Studies in pregnant women suggested some risk to fetus6|
- Esketamine has not been studied extensively in pregnant women, but has shown negative effects on exposed offspring in rats.
- Esketamine is not currently recommended for pregnant women.
- Other antidepressants, such as an SSRI or bupropion, should be considered for depression in pregnancy.
- Medication changes should ideally be made before pregnancy and should be initiated on case-by-case basis with individualized treatment.
- An appropriate dose for an adult is 56 mg (2 sprays total intranasally) administered on day 1 of treatment, then 56-84 mg (2-3 sprays total) twice weekly for 4 weeks.5
- It is important to remember that untreated depression during pregnancy is very risky and mothers should seek treatment for depression during pregnancy.
Erika Anderson MS4
Thomas W. Hale, Ph.D.
Teresa Baker MD
- Paddock, Catharine. “The FDA Approve Esketamine Nasal Spray for Severe Depression.” Medical News Today, MediLexicon International, 8 Mar. 2019, www.medicalnewstoday.com/articles/324656.php.
- Li, Xinran, et al. “Ketamine Administered Pregnant Rats Impair Learning and Memory in Offspring via the CREB Pathway.” Oncotarget, vol. 8, no. 20, 2017, doi:10.18632/oncotarget.15405.
- Li, Yanan, et al. “Long-Term Neurocognitive Dysfunction in Offspring via NGF/ ERK/CREB Signaling Pathway Caused by Ketamine Exposure during the Second Trimester of Pregnancy in Rats.” Oncotarget, vol. 8, no. 19, 2017, doi:10.18632/oncotarget.16042.
- Dong, C., et al. “Ketamine Exposure during Embryogenesis Inhibits Cellular Proliferation in Rat Fetal Cortical Neurogenic Regions.” Acta Anaesthesiologica Scandinavica, vol. 60, no. 5, 2016, pp. 579–587., doi:10.1111/aas.12689.
- “SPRAVATO™ Treatment Center.” Spravato Esketomine, www.spravatotreatmentcenter.com/.
- Payne, Jennifer L., and Samantha Meltzer-Brody. “Antidepressant Use During Pregnancy: Current Controversies and Treatment Strategies.” Clinical Obstetrics and Gynecology, vol. 52, no. 3, 2009, pp. 469–482., doi:10.1097/grf.0b013e3181b52e20.
Read the clinical study at neurosciencenews.com
Adriana Feder M.D., Sara Costi, M.D., Sarah B. Rutter, M.A., Abigail B. Collins, B.S., Usha Govindarajulu, Ph.D., Manish K. Jha, M.D., Sarah R. Horn, M.A., Marin Kautz, M.A., Morgan Corniquel, M.A., Katherine A. Collins, Ph.D., M.S.W., Laura Bevilacqua, M.D., Ph.D., Andrew M. Glasgow, M.D., Jess Brallier, M.D., Robert H. Pietrzak, Ph.D., M.P.H., James W. Murrough, M.D., Ph.D.,Dennis S. Charney, M.D.
Published Online: American Journal of Psychiatry, 5 Jan 2021 https://doi.org/10.1176/appi.ajp.2020.20050596
Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors’ previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD.
Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale–Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures.
The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events.
This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine’s full potential as a treatment for chronic PTSD.
Deborah Brauser, 18 de enero de 2021
Las infusiones intravenosas repetidas de ketamina proporcionan alivio rápido a pacientes con trastorno por estrés postraumático, señala nueva investigación.
En lo que los investigadores denominan primer estudio aleatorizado controlado de administración repetida de ketamina para tratar el trastorno por estrés postraumático crónico, 30 pacientes recibieron seis infusiones de ketamina o midazolam (utilizado como placebo psicoactivo) durante 2 semanas consecutivas.
No se registraron TRAE graves. Se produjeron algunos síntomas disociativos durante la infusión de ketamina, con los niveles más altos hacia el final de la infusión, pero éstos se habían resuelto en el momento de la siguiente evaluación 2 horas después de la infusión.
El evento adverso más comúnmente reportado en el grupo de ketamina en comparación con el midazolam después del inicio de la infusión fue la visión borrosa (53% vs. 0%), seguido de mareos (33% vs. 13%), fatiga (33% vs. 87%), dolor de cabeza (27% vs. 13%) y náuseas o vómitos (20% vs. 7%).
«En general, los resultados en esta población de pacientes indican que las infusiones repetidas de ketamina durante 2 semanas se asocian con una mejora marcada y clínicamente significativa en la sintomatología del TEPT», escriben los investigadores, y Feder los consideró «muy satisfactorios».
«También fue alentador escuchar lo que algunos de los participantes tenían que decir. Por ejemplo, algunos informaron de cómo sus síntomas y sentimientos habían cambiado en el transcurso del tratamiento con ketamina, sintiéndose más fuertes y más capaces de hacer frente a sus traumas y recuerdos.»
Añadió, sin embargo, que el estudio no fue diseñado específicamente para evaluar la ketamina para el TEPT resistente al tratamiento. «Algunos pacientes ya habían recibido varios tratamientos sin éxito, mientras que otros nunca habían sido tratados. La eficacia en el TEPT resistente al tratamiento es una cuestión importante para futuras investigaciones», dijo Feder.
En general, los resultados de esta población de pacientes muestran que las infusiones repetidas de ketamina durante dos semanas se asocian a una mejora notable y clínicamente significativa de la sintomatología del TEPT. Dra. Adriana Feder y colegas
Otras áreas que vale la pena explorar en el futuro serían la eficacia del tratamiento en pacientes con diferentes formas de trauma y si los resultados duraron más tiempo en los pacientes que recibieron ketamina más psicoterapia, señaló.
«No quiero ignorar el hecho de que los tratamientos actualmente disponibles funcionan para un número de personas con TEPT crónico. Pero dado que hay muchas más personas para las que estos tratamientos no ayudan o no ayudan lo suficiente, éste es sin duda un enfoque potencialmente muy prometedor para añadir al repertorio de tratamiento de un clínico», dijo Feder.
Enlace al estudio en Elsevier:
Igor Kungurtsev, M. D.
The recent changes in the former Soviet Union have allowed Russian and American researchers to
communicate freely for the first time since the October Revolution. Prior to these changes, the story of
Russian psychedelic research had remained a mystery in the West. The following article is one of the first
reports of psychedelic research to emerge from Russia as well as the first published outcome study of
Igor Kungurtsev, M.D. is a research associate at the Bekhterev Psychoneurological Research Institute in
St. Petersburg, Russia, and a psychiatrist in private practice. Kungurtsev is also Vice Chairman of the St.
Petersburg Transpersonal Association, and a member of the Board of Advisors of the Albert Hofmann
About five years ago, our research team obtained permission from the Central Pharmacological
Committee in Moscow to use ketamine as an adjunct to psychotherapy with alcoholics. Ketamine is an
anesthetic used in modern medicine which can also be used in subanesthetic doses to safely and reliably
induce transpersonal states with profound healing potential. This paper will review the phenomenology of
the ketamine state, the procedure for ketamine-assisted psychotherapy, and the preliminary results of our
study with alcoholic and neurotic patients.
Ketamine, 2-(o-chlorophenyl)-2-(methyl-amino) cyclohexanone HCL, has several advantages over other
psychedelics as an adjunct to psychotherapy. It is short acting, the psychoactive effects lasting about an
hour. In addition, ketamine is not scheduled like other psychedelics. In lower doses (about one sixth to
one tenth of that usually used in surgery), it induces profound transpersonal states. My colleagues and I
adopted the transpersonal paradigm as a result of our personal and clinical experience with ketamine
before we had become acquainted with the literature on psychedelics and altered states of consciousness.
At first, we attempted to use ketamine solely as a means of increasing the patient’s suggestibility. The
psychotherapist could then place suggestions of sobriety more deeply into the patient’s subconscious.
Anesthesiologists have reported that ketamine frequently induces states of confusion, feelings of death
and dying, and unpleasant hallucinations. This is known as the “emergence reaction”, and is considered to
be a negative side effect of ketamine in surgical patients who are unprepared for these psychological
Subsequently, we had the idea that we could associate these feelings of death and dying with the smell and
taste of alcohol (an aversive conditioning model). Not long after we started our research, however, we
came across situations which were incompatible with this paradigm. After ketamine injections, many of
our patients reported very strange experiences. They began to report that they felt disconnected from their
bodies, and that they were “floating” in strange worlds. Some of them, for the first time in their lives,
spoke about God, the meaning of life, and their relationships. Although we tried to help our patients form
negative associations and develop an aversion to alcohol, their experience was more profound and
mystical, sometimes with no relationship to our suggestions or psychotherapy.
At this point, I undertook a series of self-administrations which completely changed my conception of the
ketamine experience. I tried various dosages in order to choose the level most appropriate for our patients.
Three or four minutes after the first injection, I felt this world begin to disappear, and I experienced
myself as a point of consciousness which was floating in strange worlds. The most unusual feeling was
that I had no body, yet somehow “I” existed. The next development was indescribable. During the first
stage, I seemed to exist only as a point of consciousness, but still, “I” existed. Then there was a stage
where even this disembodied sense of self began to disappear, and I felt a real terror of dying. At that
moment I managed to surrender and let go. All that remained was awareness; there was no “I” as me, as
an individual point of consciousness. It was as if there existed only that which was aware of itself.
This experience profoundly changed my view of ketamine, and gave me new insight into some esoteric
concepts of Buddhism and other Eastern philosophies. It profoundly changed my understanding of death
and dying as well.
For several days after this session, I had a feeling of inner surrender, as if my life was a game that I was
playing very easily. While I performed my daily activities, I was very calm and centered inside. It was a
remarkable feeling. After this self-experimentation, we changed our paradigm and adopted a transpersonal
approach. We now refer to this treatment as “Death-Rebirth” Psychotherapy.
The research is done in a comparatively large hospital for the treatment of alcoholics near St. Petersburg.
The patients in this hospital are all voluntary. The psychotherapy is usually limited to the area of alcohol
abuse, and the goal of treatment is overcoming their so-called “alcohol denial.”
A typical patient in our ketamine program stays in the hospital about one month. During the first phase of
therapy, we treat their alcohol withdrawal syndrome and any related anxiety or affective disorders. Then,
we start rational, cognitive psychotherapy in order to establish a mental set of sobriety and a negative
attitude toward alcohol. However, we go beyond the problem of alcohol abuse to explore broader issues
including the patient’s life history, relationships, and world view.
Later in the program, we tell them that they will undergo a new treatment which will allow them to see
and feel the subconscious roots of their problems. We help our patients understand that their alcohol
problem is only a superficial symptom – the manifestation of more deeply rooted problems.
On the day of the session, we give the patient an intragluteal injection of about 150 mg. of ketamine
(approx. 2 mg. per kg.). We prefer the intramuscular route because the effect is more gradual, and the
transpersonal state lasts longer. With an intravenous injection, the effect lasts only about fifteen to twenty
minutes, but after an intramuscular injection, it lasts from about forty-five minutes to an hour.
We tell the patient that they will enter some unusual states of consciousness and that they may feel
detached from their body. We also instruct them to surrender fully to the experience. I gave up our original
approach of trying to induce something specific in the patient during the session. Under the influence of
ketamine, especially in these doses, one has no direct contact with ordinary reality. The psychotherapist
can try to influence the experience, but it will be in vain. We are available, however, to give emotional
support if the patient requests it.
As with other psychedelics, music also enhances the ketamine experience. We have found composers
whose music is particularly conducive for ketamine sessions, such as Jean Michael Jarre or Kitaro. After
forty-five minutes to an hour, the patient slowly comes back from the experience. During the recovery
period, which takes about an hour and a half or two hours, the patient begins to feel ordinary reality
returning, but part of their consciousness is still in another world, another dimension. At this point in the
session, the patient usually begins to describe their experience, and we begin some interpretation. After
the session, the patient goes to rest, and we ask them to write down a detailed report of their experience
that evening. The next day, we have a follow-up session which includes an in-depth discussion of their
experience. When several patients have ketamine sessions on the same day, we do it as group therapy. We
gather these patients in a group the day before treatment and the day after, because when they all share the
experience, it is usually more powerful.
Regarding spiritual experiences induced by ketamine, it is interesting that many people who never thought
about spirituality or the meaning of life reported having experiences that one might read about only in
spiritual texts or Eastern teachings. At the beginning of ketamine sessions, people often experience the
separation of consciousness from the body and the dissolving of the body ego. For many patients, it is a
profound insight that they can exist without their bodies as pure consciousness or pure spirit. Many of
them said that as a result of their experience, they understood the Christian notion of the separation of the
soul and the body, and that they now believe some part of them will continue to exist after death. There
were several cases where people reported contact with God, but this is usually not an anthropomorphic
figure. They describe an ocean of brilliant white light, sometimes a golden white light, which is filled with
love, bliss and energy. After coming back to ordinary consciousness, they feel sure that they have had
contact with a higher power. There were also several cases where people saw Jesus Christ approaching
them. It seems ironic that so many of our patients, through their own experience, were converted to a
more spiritual approach to life, despite living in a country where people have been brought up for
generations with atheism.
A second observation is that many patients report the existence of other dimensions or other worlds that
are parallel to ours. They usually report that these other dimensions seem as real or more real than our
own. Some patients experience this “ego death”, or the dissolving of the individual sense of self, which 1
had experienced. Of course they do not use these terms. They might say, “I ceased to exist, I disappeared,
yet still something existed. It was like I became the whole universe or the whole cosmos”. In my
experience, I also got the feeling of the collapse of space and time, and I really felt that space and time
were illusions. It was as if I had collapsed into a single point with no space and no time, and it was from
this point that the whole universe seemed to be manifesting.
Another interesting observation, although not a topic of our research, is the correlation between the type
of personality and the type of experience under the influence of ketamine. People who are very controlled
and have difficulties letting go, or who have problems with relationships, often have negative experiences
with ketamine. For them, the dissolving of the individual sense of self is horrible. For other patients who
are more relaxed and able to surrender, who have a deep capacity to love, the experience is usually
blissful, even ecstatic.
The action of ketamine is somewhat unique in comparison with other psychoactive substances. Stanislav
Grof has divided the psychedelic experience and other experiences of altered states of consciousness into
three main categories; the psychodynamic level, where people recall the past events of their lives,
especially childhood memories; the perinatal level, or the recollection of the birth experience; and the
transpersonal level, which includes the mystical experience. “Transpersonal” refers to experiences which
go beyond one’s individual personality and involve the transcendence of the spatial or temporal
boundaries of ordinary consciousness. One might also experience mythological themes or archetypal
figures like the god or goddess, or the expansion of consciousness to encompass the whole cosmos, etc.
Ketamine differs from other psychedelics in that in medium doses, it usually it does not engage the
psychodynamic level. Instead, it almost “throws” one into the transpersonal realm. The other major
psychedelics, such as LSD or mescaline, are more gradual and gentle, and in medium doses they usually
engage the psychodynamic level. To induce transpersonal states, higher doses of these substances are
Of course, the effects of ketamine are also a function of dosage. In low doses, one remains in contact with
ordinary reality, but with eyes closed one can see some strange images. They are not human forms, but
usually geometric shapes like spheres or triangles, or simply open spaces.
Following treatment, the patient is released from the hospital. Every two or three months, we see them for
follow-up visits. We have collected data on patients who have undergone ketamine-assisted
psychotherapy after spending one month in the hospital. About sixty eight per cent of these patients
remain sober for one year following treatment. This is a very high success rate in comparison with other
programs for alcoholism. In the control group, which was composed of patients who were in the same
hospital, who were the same average age, and who were in the same stage of the development of
alcoholism, the percentage who remained sober for one year was about forty-five to fifty per cent. So we
have proven statistically that the ketamine experience is very useful. We believe that these positive results
in maintaining sobriety were not achieved simply because we were more successful in establishing a set
of sobriety and a deeper negative attitude toward alcohol, but rather because of changes in the values,
relationships, and world view of these patients. They began to see other goals, other values, other
pleasures in their lives, and this was the main reason for their sobriety. For us, this was much more
interesting than the limited issue of keeping sober.
We also administered several psychological tests before and after the ketamine treatment. We gave
patients the MMPI, and after the session the scales which indicated anxiety and depression decreased
statistically, even though these patients were not primarily neurotic or depressive. The same results were
also confirmed by the Zung anxiety and depression scales, but we were interested in more than these
clinical symptoms. We also tried to measure changes in values and world view after treatment. It was
difficult to find an instrument to measure these changes, but the two scales we found most useful were the
Omega Life Changes Questionnaire by Kenneth Ring, and the Self-Assessment Spirituality Scale by
Charles Whitfield. Kenneth Ring is a professor of psychology at the University of Connecticut who has
done extensive research on near-death experiences, and he created The Life Changes Questionnaire. It
consists of some thirty questions that assess the individual’s values, goals, and attitudes toward material
things, etc. Our patients showed the most significant changes in exactly this scale. According to the results
of this questionnaire, they shifted to a more spiritual world view. We also used the Self-Assessment
Spirituality Scale by Charles Whitfield, an American researcher who has tried to introduce spirituality into
recovery from alcoholism. In addition, we developed our own instrument, called the “repertory grid”,
which measures psychosemantic fields. It measures the meanings of key words such as life, love, death,
despair, Jesus Christ, etc. Through this tool, we can measure changes in the patient’s attitude toward
various aspects of life. This scale also showed that our patients shifted to a wider, more spiritual world
Our anecdotal observations also confirmed these changes. Some patients began to write poems after their
ketamine sessions, while others began to paint. Many of them began to feel more connected with nature
and reported, for example, that after treatment they went to the countryside more often. When some
patients went back to their families, they noticed problems in their relationships, or certain idiosyncrasies
of their spouses and relatives which they were unaware of before treatment. Ketamine seems to increase
the capacity for detached observation.
I would also like to relate some unusual anecdotes connected with our research. About one year after we
began our study, a group composed of two men and one woman appeared at our hospital who were very
strange looking, wore strange clothes, and had strange, shiny eyes that seemed out of focus. They called
themselves “magicians”, and said that they sensed in their meditations and magic practice that in this
hospital, some people were throwing other souls into the “astral plane”. They had come to see what we
were doing, like “astral police”. Prior to this, we had not published the results of our work, and only a few
professionals knew about it. Also, this hospital is situated in the suburbs of St. Petersburg, and is not
widely known. So we described our work and showed them our hospital. They approved! They also told
us that they themselves used ketamine for their underground magic practice. As far as I understood from
our conversations, their practice to some extent imitates or closely parallels the practice of Carlos
Casteneda. They had gone into the forest and found power spots and power plants, and practiced
meditation there. This acquaintance was useful for us because, as it turned out, they had a tremendous
volume of underground psychedelic literature, translated into Russian. When we shifted to the
transpersonal paradigm, we began a literature search, and we sent requests to several libraries, including
the main state library in Moscow. Although they probably had this literature, it was two or three years
ago, before the changes in Russia, and they didn’t send it to us. So the magicians gave us, for example,
Peter Stafford’s Psychedelics Encyclopedia. Later, there was another interesting episode with these
magicians. One of the men told me that they also used mushrooms growing in the forest near the region of
St. Petersburg to induce psychedelic states. At first I didn’t believe him, but he gave me a dried specimen,
and I identified it in the Psychedelics Encyclopedia as Psilocybe semilanceata.
To date, the total number of patients treated with this method is about four hundred. Our results show that
ketamine-assisted psychotherapy is significantly more effective in treating alcoholism than standard nondrug
psychotherapy. In addition, ketamine-assisted psychotherapy results in positive life changes which
go beyond the limited goal of maintaining sobriety, including profound changes in values, relationships,
and world view. In the near future, we plan to continue our work with alcoholic patients and to develop
this approach further with neurotic patients using repeated ketamine sessions.
Note: The author would like to thank Robert Zanger and Blackbird Willow for their assistance in the preparation of this article.
Reprinted from the Fall 1991 issue of the Albert Hofmann Foundation bulletin.
This study aimed to develop a method that objectively measures the clinical benefits of ketamine infusions to treat complex regional pain syndrome (CRPS), thus making it possible, for the first time, to determine the optimal dosing of ketamine and duration of treatment to treat CRPS.
Materials and Methods:
All patients were diagnosed with hyperalgesia associated with CRPS. Patients underwent an outpatient, 4-day, escalating dose ketamine infusion. Hyperalgesia was measured using pain thresholds. Clinical outcome was determined without knowledge of the patient’s pain thresholds throughout treatment.
We found a correlation between pain thresholds and the intensity of pain reported by the patient at various sites of the body. We found that clinical outcomes correlated with improvement in pain thresholds. There was a plateau in pain thresholds between days 3 and 4 for the lower extremities. There was no plateau in pain thresholds observed for the upper extremities.
Our findings suggest that 4 days of treatment are sufficient for the treatment of CRPS of the lower extremities. For the upper extremities, >4 days may be required. Our study is the first to utilize quantitative sensory testing to direct the treatment of a chronic pain disorder.
Objective: Pharmacotherapy and behavioral treatments for alcohol use disorder are limited in their effectiveness, and new treatments with innovative mechanisms would be valuable. In this pilot study, the authors tested whether a single subanesthetic infusion of ketamine administered to adults with alcohol dependence and engaged in motiva- tional enhancement therapy affects drinking outcomes.
Methods: Participants were randomly assigned to a 52- minute intravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week outpatient regimen of motivational enhancement therapy. Alcohol use following the infusion was assessed with timeline followback method, with abstinence confirmed by urine ethyl glucuro- nide testing. A longitudinal logistic mixed-effects model was used to model daily abstinence from alcohol over the 21 days after ketamine infusion.
Results: Participants (N=40) were mostly middle-aged (mean age=53 years [SD=9.8]), predominantly white (70.3%), and largely employed (71.8%) and consumed an average of five drinks per day prior to entering the study. Ketamine significantly increased the likelihood of abstinence, delayed the time to re- lapse, and reduced the likelihood of heavy drinking days com- pared with midazolam. Infusions were well tolerated, with no participants removed from the study as a result of adverse events.
Conclusions: A single ketamine infusion was found to im- prove measures of drinking in persons with alcohol de- pendence engaged in motivational enhancement therapy. These preliminary data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use dis- order. Further research is needed to replicate these promis- ing results in a larger sample.
Am J Psychiatry 2020; 177:125–133; doi: 10.1176/appi.ajp.2019.19070684
Sub-anesthetic ketamine infusions may benefit a range of psychiatric conditions, including alcohol and cocaine use disorders. Currently, there are no effective pharmacological treatments for cannabis use disorder.
The objective of this uncontrolled proof of concept trial was to test the feasibility, tolerability, and potential therapeutic effects of integrating ketamine infusions with a behavioral platform of motivational enhancement therapy and mindfulness-based relapse prevention in treating cannabis use disorder (CUD).
Eight cannabis-dependent individuals (four female, four male) receiving motivational enhancement therapy and mindfulness-based relapse prevention behavioral treatments completed this single-blind outpatient 6-week study. Participants received either one or two infusions of ketamine (0.71 mg/kg [infusion 1]; 1.41 mg/kg [infusion 2] for non-responders) during the study. Participants self-reported cannabis use (Timeline Follow-Back) and underwent an assessment of confidence in abstaining from using cannabis (Drug-Taking Confidence Questionnaire) at predetermined time points throughout the study.
Ketamine infusions were well-tolerated and there were no adverse events. Frequency of cannabis use decreased significantly from baseline (B = 5.1, s.e = 0.7) to the week following the first infusion (B = 0.8, s.e = 0.412), and remained reduced at the end of the study (B = 0.5, s.e = 0.3). Participants’ confidence in their ability to abstain from cannabis in potentially triggering situations increased significantly from baseline to the end of study.
These findings suggest that combining ketamine with behavioral therapy is feasible,tolerable, and potentially helpful, in treating cannabis-dependent individuals.
With a rise in the incidence of autoimmune diseases (AiD), health care providers continue to seek out more efficacious treatment approaches for the AiD patient population. Classic serotonergic psychedelics have recently been gaining public and professional interest as novel interventions to a number of mental health afflictions. Psychedelics have also been shown to be able to modulate immune functions, however, while there has been great interest to researching into their psychotherapeutic applications, there has so far been very little exploration into the potential to treat inflammatory and immune-related diseases with these compounds. A handful of studies from a variety of fields suggest that psychedelics do indeed have effects in the body that may attenuate the outcome of AiD. This literature review explores existing evidence that psychedelic compounds may offer a potential novel application in the treatment of pathologies related to autoimmunity. We propose that psychedelics hold the potential to attenuate or even resolve autoimmunity by targeting psychosomatic origins, maladaptive chronic stress responses, inflammatory pathways, immune modulation and enteric microbiome populations.
D-Serine is an endogenous NMDA receptor co-agonist that activates synaptic NMDA receptors modulating neuronal networks in the cerebral cortex and plays a key role in long-term potentiation of synaptic transmission. D-serine is associated with NMDA receptor neurotoxicity and neurodegeneration and elevated D-serine concentrations have been associated with Alzheimer’s and Parkinsons’ diseases and amyotrophic lateral sclerosis. Previous studies have demonstrated that the ketamine metabolites (rac)-dehydronorketamine and (2S,6S)-hydroxynorketamine decrease intracellular D-serine concentrations in a concentration dependent manner in PC-12 cells. In the current study, PC-12 cells were incubated with a series of ketamine metabolites and the IC50 values associated with attenuated intracellular D-serine concentrations were determined. The results demonstrate that structural and stereochemical features of the studied compounds contribute to the magnitude of the inhibitory effect with (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine displaying the most potent inhibition with IC50 values of 0.18 ± 0.04 nM and 0.68 ± 0.09 nM. The data was utilized to construct a preliminary 3D-QSAR/pharmacophore model for use in the design of new and more efficient modulators of D-serine.
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ2 = 125.29, p < 0.001, χ2 = 9.08, p = 0.003, χ2 = 8.14, p = 0.004, χ2 = 19.48, p < 0.001, χ2 = 25.62, p < 0.001, and χ2 = 16.79, p < 0.001, respectively). Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
© 2020 S. Karger AG, Basel
The objective of this study was to investigate the safety of repeated parenteral ketamine for depression. An electronic survey inquiring about the frequency of adverse events was distributed to providers of parenteral ketamine for depression. In addition, the investigators conducted a search of published studies describing six or more repeated parenteral ketamine treatments administered to individuals for depression, and extracted reported adverse events. The survey was sent to 69 providers, of which 36 responded (52% response rate); after eliminating those that were incomplete, 27 were included in the analysis. The providers in the analysis collectively reported treating 6630 patients with parenteral ketamine for depression, one-third of whom received more than 10 treatments. Only 0.7% of patients experienced an adverse eect that required discontinuation of ketamine. Psychological distress during the treatment was the most frequent cause. Other adverse events were extremely rare (such as bladder dysfunction (0.1%), cognitive decline (0.03%) and psychotic symptoms (0.03%)). Among the 20 published reports of repeated parenteral ketamine treatments, rates of significant adverse events resulting in discontinuation were low (1.2%). The rate of adverse eects reported in the survey and the published literature is low, and suggests that long-term treatment of depression with ketamine is reasonably safe.
Keywords: ketamine; major depressive disorder; depression; addiction
Major depressive disorder (MDD) is a common mental health disorder that brings severe disease burden worldwide. Traditional antidepressants are mainly targeted at monoamine neurotransmitters, with low remission rates and high recurrence rates. Ketamine is a noncompetitive glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist, and its rapid and powerful antidepressant effects have come to light. Its antidepressant mechanism is still unclarified. Research found that ketamine had not only antagonistic effect on NMDAR but also strong immunomodulatory effect, both of which were closely related to the pathophysiology of MDD. Although there are many related studies, they are relatively heterogeneous. Therefore, this review mainly describes the immune mechanisms involved in MDD and how ketamine plays an antidepressant role by regulating peripheral and central immune system, including peripheral inflammatory cytokines, central microglia, and astrocytes. This review summarizes the related research, finds out the deficiencies of current research, and provides ideas for future research and the development of novel antidepressants.
El estudio completo: https://www.degruyter.com/document/doi/10.1515/tnsci-2020-0167/html
The use of ketamine for treatment of comorbid pain, depression, and substance use disorders (SUDs) is becoming an option of increasing interest, as multiple clinical studies demonstrate its efficacy. Ketamine’s efficacy in this diagnostically complex population is mechanistically based on a wide array of affected brain areas in addition to presynaptic neurons of the spine. Efficacy has been shown in both depressive and pain disorders with durability lasting 3 to 4 weeks after discontinuation of ketamine. Although ketamine itself is a drug of potential abuse when used recreationally, its lasting effects without repeated daily use have also shown promise for patients with SUDs. Assisted psychotherapy concurrent with ketamine treatment can help dependent patients cultivate new perceptions and ideals consistent with sobriety. Decreased opiate cravings in patients with SUDs may be related to ketamine’s effects on reducing opiate-induced hyperalgesia. Given this and additional properties, ketamine can help reduce opiate medication burden, augment opiates in the hospice setting, or acutely alleviate symptoms of opiate withdrawal. [Psychiatr Ann. 2018;48(4):180–183.]
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder
Objective: Patients with major depressive disorder often have limited response to first-line and second-line medications; hence, novel pharmacological treatments are needed for treatment-resistant depression (TRD). Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has demonstrated rapid antidepressant effects in patients with TRD. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence for efficacy and safety of racemic ketamine and to provide recommendations for its use in clinical practice.
Methods: A systematic review was conducted with computerized search of electronic databases up to January 31, 2020 using combinations of search terms, inspection of bibliographies, and review of other ketamine guidelines and consensus statements. The level of evidence and lines of treatment were assigned according to CANMAT criteria. Recommendations were given in question-answer format.
Results: Intravenous (IV) racemic ketamine given as a single infusion has Level 1 evidence for efficacy in adults with TRD. The evidence for multiple infusions, given as an acute series or as ongoing maintenance treatment, is limited to Level 3. Adverse events associated with ketamine infusions include behavioral (e.g., dissociative symptoms) and physiological (e.g., hypertension) events. There is only Level 3 or 4 evidence for non-IV formulations of racemic ketamine. Consensus recommendations are given for clinical administration of IV ketamine including patient selection, facility and personnel issues, monitoring, and maintaining response.
Conclusions: Single-dose IV racemic ketamine is a third-line recommendation for adults with TRD. The need for repeated and maintenance ketamine infusions should be carefully assessed on a case-by-case basis with consideration of potential risks and benefits. Because of limited evidence for efficacy and risk for misuse and diversion, the use of oral and other formulations of racemic ketamine should be limited to specialists with ketamine-prescribing expertise and affiliations with tertiary or specialized centers.
Background: Racemic (R,S)-ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)-ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment-resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of ketamine. However, recent meta-analyses have suggested that IV racemic ketamine may be more potent than IN-(S)-ketamine.
Methods: We retrospectively analyzed clinical outcomes in 15 Veterans with comorbid TRD and post-traumatic stress disorder (PTSD) who underwent ketamine treatment at the VA San Diego Neuromodulation Clinic. All Veterans included in this analysis were given at least 6 intranasal (IN)-(S)-ketamine treatments prior to switching to treatment with IV racemic ketamine.
Results: Veterans receiving ketamine treatment ( across both IN-(S)-ketamine and IV-(R,S)-ketamine) showed significant reductions in both the Patient Health Questionnaire-9 (PHQ-9), a self-report scale measuring depression symptoms (rm ANOVA F(14,42) = 12.6, p < 0.0001), and in the PTSD checklist for DSM-5 (PCL-5), a self-report scale measuring PSTD symptoms (rm ANOVA F(13,39) = 5.9, p = 0.006). Post hoc testing revealed that PHQ-9 scores were reduced by an average of 2.4 ± 1.2 compared to baseline after (S)-ketamine treatments (p = 0.1) and by an average of 5.6 ± 1 after IV-ketamine treatments (p = 0.0003) compared to pretreatment baseline scores. PCL-5 scores were reduced by an average of 4.3 ± 3.3 after IN (S)-ketamine treatments (p = 0.6) and 11.8 ± 3.5 after IV-ketamine treatments (p = 0.03) compared to pretreatment baseline scores.
Conclusions: This work suggests that off-label IV-(R,S)-ketamine could be considered a reasonable next step in patients who do not respond adequately to the FDA-approved IN-(S)-ketamine. Further double-blinded, randomized controlled trials are warranted to assess whether IV racemic ketamine is more effective than IN-(S)-ketamine.
Keywords: (S)-ketamine; depression; ketamine.
© 2022 Pharmacotherapy Publications, Inc.
Estudios medicos sobre la Neuroretroalimentación
- Ashlie N. Bell, PhDSaybrook University / NeuroGrove, P.C. / Integrative Neurotherapy Center of Colorad
- Donald Moss, PhDSaybrook University
- Robert J. Kallmeyer, PhDSaybrook University
1- Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
2- Department of Clinical Psychology, Social Determinants of Health Research Center, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
3- Department of Neurology, Faculty of Medicine, Vali Asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran.
4- Department of Physiology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Basic and Clinical Neuroscience, 2020
Introduction: Migraine is considered one of the most common primary headache disorders. Migraine attacks may occur due to a lack of sleep. Furthermore, sleep is regarded as one of the smoothing factors of migraine pain. Patients with sleep disorders often suffer from headaches when they wake up compared with healthy individuals.
Methods: This research was a quasi-experimental study with a pretest-posttest design and a 2-month follow-up. The samples included 20 migraine patients within the age range of 15 to 55 years who were selected as volunteers for treatment by the neurologists and psychiatrists during 2017. The initial evaluation was then conducted based on the inclusion and exclusion criteria and using the Ahvaz migraine questionnaire, and Pittsburgh sleep quality index. The patients were randomly assigned to two neurofeedback (n=10) and transcranial direct current stimulation (tDCS) (n=10) groups and evaluated three times. The obtained data were analyzed by the repeated measures ANCOVA and Chi-square test in SPSS.
Results: Based on the scores of both groups, no significant difference was observed between neurofeedback and tDCS groups. However, based on the results, neurofeedback decreased sleep latency, whereas tDCS increased sleep efficiency. Overall, these two treatments were effective in improving subjective sleep quality and sleep quality.
Conclusion: Both neurofeedback and tDCS treatments could significantly enhance sleep quality of the patients in the posttest and 2-month follow-up. Given the effectiveness of both treatments, neurofeedback and tDCS are recommended to be used for improving the sleep status of patients with migraine.
Martijn Arns · C. Richard Clark · Mark Trullinger · Roger deBeus · Martha Mack · Michelle Aniftos
© The Author(s) 2020
Stimulant medication and behaviour therapy are the most often applied and accepted treatments for Attention-Deficit/ Hyperactivity-Disorder (ADHD). Here we explore where the non-pharmacological clinical intervention known as neuro- feedback (NFB), fits on the continuum of empirically supported treatments, using standard protocols. In this quantitative review we utilized an updated and stricter version of the APA guidelines for rating ‘well-established’ treatments and focused on efficacy and effectiveness using effect-sizes (ES) and remission, with a focus on long-term effects. Efficacy and effec- tiveness are compared to medication and behaviour therapy using benchmark studies. Only recent systematic reviews and meta-analyses as well as multi-centre randomized controlled trials (RCT’s) will be included. Two meta-analyses confirmed significant efficacy of standard neurofeedback protocols for parent and teacher rated symptoms with a medium effect size, and sustained effects after 6–12 months. Four multicenter RCT’s demonstrated significant superiority to semi-active control groups, with medium-large effect sizes end of treatment or follow-up and remission rates of 32–47%. Effectiveness in open- label studies was confirmed, no signs of publication bias were found and no significant neurofeedback-specific side effects have been reported. Standard neurofeedback protocols in the treatment of ADHD can be concluded to be a well-established treatment with medium to large effect sizes and 32–47% remission rates and sustained effects as assessed after 6–12 months.
Recent reviews have proposed that scientifically validated standard EEG neurofeedback (NF) protocols are an efficacious and specific treatment for attention-deficit hyperactivity disorder (ADHD). Here, we review the current evidence for the treatment efficacy and clinical effectiveness of NF in ADHD to investigate whether NF treatment personalization (standard protocols matched to the electrophysiological features of ADHD) and combination with other interventions (psychosocial, sleep hygiene and nutritional advice) might yield superior long-term treatment outcomes relative to non-personalized NF and medication monotreatments.
The electronic databases PubMed and PsycINFO were systematically searched using our key terms. Of the 38 resulting studies, 11 randomized controlled trials (RCTs) and open-label studies were eligible for inclusion. Studies were analyzed for effect sizes and remission rates at the end of treatment and at follow-up. The effects of personalized and multimodal NF treatments were compared to non-personalized NF monotreatments and with two benchmark medication studies.
The analysis of RCTs indicated that the long-term effects of personalized NF interventions were superior to non-personalized NF and comparable to those of medication alone or in combination with behavioral intervention. The analysis of open-label trials further indicates that the interaction of NF with parental interventions, sleep and nutritional advice might yield superior clinical effectiveness relative to NF and medication monotreatments.
Personalized and multimodal NF interventions seem to yield superior treatment efficacy relative to NF alone and superior clinical effectiveness relative to medication. We propose that treatment outcomes may be further enhanced by adjusting NF non-specific factors (eg, reinforcement contingencies) to specific ADHD characteristics (eg, reward sensitivity). Future NF research should focus on the systematic evaluation of the treatment outcomes of personalized and multimodal treatments.
Estudio completo: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920604/
Major depressive disorder (MDD) is the leading cause of disability worldwide. Neurofeedback training has been suggested as a potential additional treatment option for MDD patients not reaching remission from standard care (i.e., psychopharmacology and psychotherapy). Here we systematically reviewed neurofeedback studies employing electroencephalography, or functional magnetic resonance-based protocols in depressive patients. Of 585 initially screened studies, 24 were included in our final sample (N = 480 patients in experimental and N = 194 in the control groups completing the primary endpoint). We evaluated the clinical efficacy across studies and attempted to group studies according to the control condition categories currently used in the field that affect clinical outcomes in group comparisons. In most studies, MDD patients showed symptom improvement superior to the control group(s). However, most articles did not comply with the most stringent study quality and reporting practices. We conclude with recommendations on best practices for experimental designs and reporting standards for neurofeedback training.
Keywords: Biofeedback; Electroencephalography; Functional magnetic resonance imaging; Major depressive disorder; Neurofeedback; Neuroimaging; Real-time fMRI; Self-regulation.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Estudios clínicos sobre la estimulación magnética transcraneal repetitiva (EMTr)
Amin et al. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2020) 56:19
The Egyptian Journal of Neurology, https://doi.org/10.1186/s41983-019-0140-5 Psychiatry and Neurosurgery
Randa Amin1, Tamer Emara1*, Samia Ashour1, Mahmoud Hemeda1, Nahed Salah Eldin1, Salma Hamed1, Sara Shouman2 and Mohamed Shouman3
Objective: The aim of the study was to examine the prophylactic role of repetitive transcranial magnetic stimulation (rTMS) on the frequency, and severity of migraine attacks in episodic migraineurs who failed medical treatment.
Methods: A randomized double-blinded placebo-controlled study was designed to assess the effect of 5 Hz rTMS applied over the left dorsolateral prefrontal cortex (LDLPFC ) in 33 migraineurs. Patients were followed up for 1 month before receiving rTMS, and for another month after the sessions by a headache diary. The primary outcome measure was the achievement of 50% reduction in the number of migraine attacks. Secondary outcome measures included migraine days, assessment of migraine attack severity, disability by HIT-6, and side-effects to the procedure.
Results: The study revealed that 69.2% of the active treatment group achieved 50% or more reduction in the number of migraine attacks versus 25% of cases in the control group (p = 0.02). The absolute number of migraine attacks was reduced by 3.1 vs 1.5 in the active and control group, respectively. The number of cases with severe HIT-6 scores was reduced by 46.2% in active treatment group versus a 7.1% reduction in the control group (p = 0.02).
Conclusion: High-frequency rTMS applied to LDLPFC can reduce the number of migraine attacks by 50% or more in almost 70% of a sample of episodic migraineurs with a concomitant decrease in functional disability.
Trial registration: ClinicalTrials.gov, Identifier: NCT04031781. Registered 23 July 2019—retrospectively registered at https://clinicaltrials.gov/ct2/show/NCT04031781?term=Migraine+Prophylaxis&recrs=ce&type=Intr&cond=Migraine&rank=9
Repetitive transcranial magnetic stimulation (rTMS), a noninvasive brain stimulation technique, has emerged as a promising treatment for mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Currently, however, the effectiveness of this therapy is unclear because of the low statistical power and heterogeneity of previous trials. The purpose of the meta-analysis was to systematically characterize the effectiveness of various combinations of rTMS parameters on different cognitive domains in patients with MCI and AD. Thirteen studies comprising 293 patients with MCI or AD were included in this analysis. Random-effects analysis revealed an overall medium-to-large effect size (0.77) favoring active rTMS over sham rTMS in the improvement of cognitive functions. Subgroup analyses revealed that (1) high-frequency rTMS over the left dorsolateral prefrontal cortex and low-frequency rTMS at the right dorsolateral prefrontal cortex significantly improved memory functions; (2) high-frequency rTMS targeting the right inferior frontal gyrus significantly enhanced executive performance; and (3) the effects of 5–30 consecutive rTMS sessions could last for 4–12 weeks. Potential mechanisms of rTMS effects on cognitive functions are discussed.
Jean-Pascal Lefaucheur et al (2020)
A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcra- nial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150–206]. These updated recommendations take into account all rTMS publications, includ- ing data prior to 2014, as well as currently reviewed literature until the end of 2018. Level A evidence (definite efficacy) was reached for: high-frequency (HF) rTMS of the primary motor cortex (M1) contralat- eral to the painful side for neuropathic pain; HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC) using a figure-of-8 or a H1-coil for depression; low-frequency (LF) rTMS of contralesional M1 for hand motor recovery in the post-acute stage of stroke. Level B evidence (probable efficacy) was reached for: HF-rTMS of the left M1 or DLPFC for improving quality of life or pain, respectively, in fibromyalgia; HF-rTMS of bilateral M1 regions or the left DLPFC for improving motor impairment or depression, respec- tively, in Parkinson’s disease; HF-rTMS of ipsilesional M1 for promoting motor recovery at the post-acute stage of stroke; intermittent theta burst stimulation targeted to the leg motor cortex for lower limb spas- ticity in multiple sclerosis; HF-rTMS of the right DLPFC in posttraumatic stress disorder; LF-rTMS of the right inferior frontal gyrus in chronic post-stroke non-fluent aphasia; LF-rTMS of the right DLPFC in depression; and bihemispheric stimulation of the DLPFC combining right-sided LF-rTMS (or continuous theta burst stimulation) and left-sided HF-rTMS (or intermittent theta burst stimulation) in depression. Level A/B evidence is not reached concerning efficacy of rTMS in any other condition. The current recom- mendations are based on the differences reached in therapeutic efficacy of real vs. sham rTMS protocols, replicated in a sufficient number of independent studies. This does not mean that the benefit produced by rTMS inevitably reaches a level of clinical relevance.
! 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nervenheilkunde 2020; 39(04): 213-221
© Georg Thieme Verlag KG Stuttgart · New York
Transkranielle Magnetstimulation zur Behandlung von Depressionen bei Schwangeren Eine Übersicht
Transcranial magnetic stimulation in the treatment of depression during pregnancy A review
Tobias Hebel, Martin Schecklmann, Berthold Langguth
Gegenstand und Ziel In dieser Übersichtsarbeit sollen die Wirksamkeit und Sicherheit der repetitiven transkraniellen Magnetstimulation (rTMS) für die Patientengruppe depressiv erkrankter Schwangerer evaluiert werden.
Material und Methoden Es wurde eine Datenbankrecherche auf Pubmed durchgeführt, um alle relevanten Original- und Übersichtsarbeiten zu dem Thema zu identifizieren und zu analysieren
Ergebnisse Zusätzlich zu einer Reihe von Fallberichten existieren 3 kontrollierte Studien zur Behandlung depressiver Schwangerer mittels rTMS. Der Datenlage nach scheint die rTMS sowohl für die schwangeren Patientinnen als auch ihre ungeborenen Kinder sicher zu sein. Es wurden keine postnatalen negativen Wirkungen auf die Kindesentwicklung berichtet.
Schlussfolgerung rTMS stellt eine vielversprechende Behandlungsoption dar. Weitere Studien mit größeren Teilnehmerzahlen sind notwendig, um den Stellenwert der rTMS in einer multimodalen Depressionsbehandlung in der Schwangerschaft zu klären.
Arch Womens Ment Health. 2014 Aug;17(4):311-5. doi: 10.1007/s00737-013-0397-0. Epub 2013 Nov 20.
The aim of the present study was to assess the safety and effectiveness of high-frequency repetitive transcranial magnetic stimulation (rTMS) in pregnant patients with depression. Thirty depressed pregnant patients received rTMS over the left prefrontal cortex for 6 days in a week, from Monday to Saturday for 3 weeks. The rTMS intensity was set at 100% of the motor threshold. A 25-Hz stimulation with a duration of 2 s was delivered 20 times with 30-s intervals. A session comprised 1,000 magnetic pulses. Depression was rated using the 17-item Hamilton depression rating scale (HAMD) before and after treatment. Response was defined as a 50% reduction of the HAMD score. Patients with HAMD scores less than 8 were considered to be in remission. The mean HAMD score for the study group decreased from 26.77 ± 5.58 to 13.03 ± 6.93 (p < 0.001) after 18 sessions of rTMS. After the treatment period, 41.4% of the study group demonstrated significant mood improvements as indexed by a reduction of more than 50% on the HAMD score. In addition, 20.7% attained remission (HAMD score < 8), 34.5% achieved a partial response, and 3.4% had worsening in HAMD scores at the end of treatment. Treatment was well tolerated, and no significant adverse effects were reported. rTMS was well tolerated and found to be statistically and clinically effective in pregnant patients with treatment-resistant depression. This study contributed to the existing evidence of the antidepressant effect of rTMS in the treatment of depression in pregnancy.
The aim of this paper is to present the clinical data analysis results from a service delivering repetitive transcranial magnetic stimulation (rTMS) for people with cocaine-use disorder (CUD).
The study was a retrospective investigation of routinely collected data on patients receiving rTMS between 2018 and 2019. Measures used were a cocaine craving Visual Analogue Scale (VAS), Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire (PHQ-9) self-rated depression measures.
The outcome data of 10 patients with CUD were analysed. There was a statistically significant reduction and a large effect size on CUD and depression scales. Conclusions: Reductions in craving and depression indicate the potential benefits to patients and to society of rTMS in treating CUD. Further sufficiently powered RCTs are warranted with studies focusing on the optimization of rTMS treatment and exploring the underlying mechanisms.
New antidepressant treatments are needed that are effective, rapid acting, safe, and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Drug Administration for treatment-resistant depression. Recent methodological advances suggest that the current iTBS protocol might be improved through 1) treating patients with multiple sessions per day at optimally spaced intervals, 2) applying a higher overall pulse dose of stimulation, and 3) precision targeting of the left dorsolateral prefrontal cortex (DLPFC) to subgenual anterior cingulate cortex (sgACC) circuit. The authors examined the feasibility, tolerability, and preliminary efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), an accelerated, high-dose resting-state functional connectivity MRI (fcMRI)–guided iTBS protocol for treatment-resistant depression.
Twenty-two participants with treatment-resistant depression received open-label SAINT. fcMRI was used to individually target the region of the left DLPFC most anticorrelated with sgACC in each participant. Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) were delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold (adjusted for cortical depth). Neuropsychological testing was conducted before and after SAINT.
One participant withdrew, leaving a sample size of 21. Nineteen of 21 participants (90.5%) met remission criteria (defined as a score <11 on the Montgomery-Åsberg Depression Rating Scale). In the intent-to-treat analysis, 19 of 22 participants (86.4%) met remission criteria. Neuropsychological testing demonstrated no negative cognitive side effects.
SAINT, an accelerated, high-dose, iTBS protocol with fcMRI-guided targeting, was well tolerated and safe. Double-blinded sham-controlled trials are needed to confirm the remission rate observed in this initial study.
HEART RATE DECELERATION (HRD) AS A LOW COST SCALABLE INDICATOR OF TARGET ENGAGEMENT DURING SAINT FOR TREATMENT RESISTANT DEPRESSION (TRD) John Coetzee 1,2, Clive Veerapal 2, Fahim Barmak 2, Seble Adinew 2, Nolan Williams 2. 1 Rehabilitation Service, Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto, CA, USA; 2Psychiatry and Behavioral Sciences,Stanford University School of Medicine, Stanford, CA, USA Abstract Prior research has shown that repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS) can induce acute time-limited heart rate deceleration (HRD) when applied to the left dorsolateral prefrontal cortex (L-DLPFC), and that the amount of deceler- ation may related to treatment response for patients with treatment resistant depression (TRD) (Iseger et al. 2020). This deceleration appears to result from activation of a neural circuit involving L-DLPFC, subgenual anterior cingulate cortex (sgACC), and vagus nerve, and may be useful as an indicator of target engagement that is less costly and more scalable than neuroimaging with functional magnetic resonance imaging (fMRI) or electroencephalography (EEG). In this study, we will extend prior HRD results to data from a now completed sham-controlled study involving the application of a novel form of iTBS treatment, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), in which 30 patients with treatment resistant depression (TRD) underwent iTBS 10 times a day for 5 days with treatments spaced 1 hour apart. Heart rate data was collected using a Neuroconn ECG device. We hypothesize that HRD will be evident during treatment application, in the active condition. We further hypothesize that the amount of HRD (reflected in the slope of the RR intervals) will be predictive of both treatment response and remission, according to the MADRS, at the im- mediate post and one-month follow up timepoints, in the active condition. We also hypothesize that the amount of HRD will be predictive of the amount of reduction in anhedonia at the immediate post and one-month follow up timepoints (as reflected by questions 7 and 8 of the MADRS). Analysis will be conducted using Kubios and SPSS. These results will contribute to the growing body of work indicating HRD can serve as a low cost and scalable marker of target engagement during neuromodulation for depression. Keywords: heart rate deceleration, TMS, iTBS
Estudios medicos sobre el uso de la realidad virtual (solo disponible en alemán)
Behaviour Change (2018), 35, 152–166 doi:10.1017/bec.2018.15
Rachel K. Chesham, John M. Malouff* and Nicola S. Schutte
University of New England, Armidale, New South Wales, Australia
*Corresponding author. John M. Malouff, University of New England, School of Psychology, Armidale NSW 2351, Australia. Email: email@example.com
Social anxiety is a common, debilitating psychological problem. In the present study, two meta-analyses examined the efficacy of virtual reality exposure therapy for social anxiety. The first meta-analysis tested whether virtual reality exposure therapy reduces social anxiety more than a waitlist control condition. The results of the first meta-analysis, consisting of six studies and 233 participants, showed a significant overall effect size, indicating that virtual reality exposure therapy was effective in reducing social anxiety. The second meta-analysis tested whether the standard treatment for social anxiety, which includes in vivo or imaginal exposure, leads to greater effects than virtual reality exposure therapy. The second meta-ana- lysis, consisting of seven studies and 340 total participants, showed essentially no difference in effect sizes between virtual reality exposure and in vivo or imaginal exposure. The results of the two meta-analyses support the use of virtual reality in the treatment of social anxiety.
Keywords: exposure therapy; meta-analysis; social anxiety; virtual reality
Social anxiety is characterised by fear of social situations and of interactions with others. Individuals experiencing social anxiety frequently avoid social situations due to fear of public scrutiny and negative evaluation (Hofmann & DiBartolo, 2014). Research findings indicate that public speaking is the most prevalent social fear (Furmark, 2002; Ruscio et al., 2008). Other common social fears include interact- ing with strangers, dating, and going to parties (Hofmann, Heinrichs, & Moscovitch, 2004). Research findings show that these fears can cause impairments in social functioning and are associated with lower levels of educational attainment, higher risk of unemployment, and difficulties in forming intim- ate relationships (Crome et al., 2015; Fehm, Pelissolo, Furmark, & Wittchen, 2005).
Despite the various harmful impacts of high social anxiety, few individuals with social anxiety seek professional help (Crome et al., 2015; Fehm et al., 2005). One possible reason for the low rate of help seeking might be that social anxiety leads these individuals to avoid interactions with mental health care providers, just as they avoid interactions with others.
Socially anxious individuals may meet criteria for a diagnosis of social anxiety disorder, as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association, 2013). According to the DSM-5, a diagnosis of social anxiety disorder (also known as social phobia) reflects clinically significant levels of social anxiety. Furthermore, the DSM-5 includes a ‘performance only’ specifier for individuals fearing only public speaking or performance situations.
Anxiety in social situations is a common human experience (Ruscio, 2010). Therefore, some experts argue it is best to conceptualise social anxiety as existing along a continuum ranging from fears that are adaptive to those that cause substantial impairment (Hofmann & DiBartolo, 2014). Ruscio (2010) suggested that all levels of social anxiety are important to consider and that researchers may overlook important information by excluding milder cases that fall below the diagnostic threshold.
© The Author(s) 2018
Behaviour Change 153
Theoretical and Treatment Models of Social Anxiety
Cognitive behaviour therapy (CBT) is the first-line treatment for social anxiety (Pilling et al., 2013). While the main evidence-based CBT tools for social anxiety include exposure, cognitive restructuring, social skills training and relaxation training, standard treatment almost always includes exposure as a key component (Heimberg, 2002).
The therapist and the client typically generate a hierarchy of social situations to use in gradual in vivo or imaginal exposure (Deacon & Abramowitz, 2004; Rodebaugh, Holaway, & Heimberg, 2004). In vivo exposure involves direct confrontation of actual feared stimuli, whereas imaginal exposure involves visualising feared situations (Olatunji, Cisler, & Deacon, 2010). The client gradually confronts each situation, from least to most feared, and engages with each item until anxiety decreases (Rodebaugh et al., 2004).
There are two prevailing theoretical models related to learning that explain how exposure therapy reduces anxiety (Abramowitz, 2013). Emotional processing theory (Foa & Kozak, 1986) and the inhibi- tory learning model (Craske et al., 2008) both postulate that exposure allows individuals to learn cor- rective information about a feared stimulus. Emotional processing theory specifically postulates that feared stimuli activate a fear structure (Foa & Kozak, 1986). When corrective information is incom- patible with this fear structure, it is replaced with a new, non-fear structure (Foa & Kozak, 1986). However, the inhibitory learning model emphasises tolerating rather than replacing fear (Craske et al., 2008). It posits that while old, fear-based learning is not erased by extinction, new learning can inhibit its expression (Craske et al., 2008).
A large body of research supports the efficacy of in vivo and imaginal exposure treatments for redu- cing symptoms of social anxiety, although the methods do not work for all individuals with social anx- iety (e.g., Acarturk, Cuijpers, van Straten, & de Graaf, 2009; Feske & Chambless, 1995; Gould, Buckminster, Pollack, Otto, & Massachusetts, 1997; Powers, Sigmarsson, & Emmelkamp, 2008; Turner, Beidel, & Jacob 1994).
Virtual Reality Exposure Therapy
In recent years, exposure therapy through virtual reality has gained substantial attention as an inter- vention for social anxiety (Powers & Emmelkamp, 2008; Wallach, Safir, & Bar-Zvi, 2009). Virtual reality technology integrates computer graphics, visual displays, motion tracking and other sensory devices to give the user a multisensory and realistic experience (Bush, 2008; Krijn, Emmelkamp, Olafsson, & Biemond, 2004; Powers & Emmelkamp, 2008). A head-mounted display is typically used to immerse clients in the virtual environment (Krijn et al., 2004).
During virtual reality exposure therapy (VRET), the client confronts computer-generated simula- tions of feared situations (Anderson et al., 2013). Trained therapists conduct the treatment in a private, safe, and controlled environment (Bush, 2008). Virtual technology is programmable, and environ- ments can be customised to clients’ specific social anxieties, in accordance with their fear and avoid- ance hierarchy (Krijn et al., 2004; Vanni et al., 2013).
VRET may be useful in addressing the shortcomings of established methods of exposure, particu- larly in relation to cost-effectiveness, convenience, treatment acceptability, treatment availability, and difficulties with clients visualising scenes during imaginal exposure (Anderson et al., 2013; Choy, Fyer, & Lipsitz, 2007; Krijn et al., 2004). Furthermore, VRET offers an appealing and novel treatment approach, and may be useful for those who show reluctance toward participating in vivo or imaginal exposure (Benedek & Wynn, 2016; Bush, 2008). Because of these advantages, VRET might have the potential to lead individuals to seek treatment who otherwise might not do so (Powers & Emmelkamp, 2008).
The Efficacy of Virtual Reality Exposure Therapy for Social Anxiety
To date, three meta-analyses have explored the efficacy of VRET for a range of anxiety disorders (Opriş et al., 2012; Parsons & Rizzo, 2008; Powers & Emmelkamp, 2008). One other meta-analysis
154 Rachel K. Chesham et al.
(Kampmann, Emmelkamp, & Morina, 2016) investigated the efficacy of treating social anxiety with a variety of technological interventions, including VRET.
Parsons and Rizzo (2008) investigated the pre-post effects of VRET for social phobia and reported a meta-analytic effect size of 0.96, 95% CI [0.34, 1.59], indicating a reduction in anxiety symptoms follow- ing VRET. However, the authors only analysed results for VRET conditions and did not compare their findings to waitlist control groups or standard treatments, making it difficult to determine the relative efficacy of VRET. In contrast, Powers and Emmelkamp (2008) did make a comparison between VRET and control conditions for two social phobia studies. They reported a between-groups, meta-analytic Hedges’ g of 0.73 (no reported confidence interval), indicating that VRET was more efficacious than con- trol conditions in the treatment of social anxiety. The meta-analysis combined waitlist control conditions and standard exposure control conditions in one meta-analysis, making the results hard to interpret.
More recently, Opriş et al. (2012) and Kampmann, Emmelkamp, and Morina (2016) examined the efficacy of VRET compared to waitlist controls. Opriş et al. (2012) reported a d of 1.01, 95% CI [0.69, 1.33] across three social phobia studies, indicating VRET outperformed waitlist on outcome measures of social anxiety. Kampmann, Emmelkamp, and Morina (2016) reported a similarly large and signifi- cant effect size across three studies, with g = 0.82, 95% CI [0.13, 1.51]. Both authors also compared VRET to standard, empirically supported treatments for social anxiety, including in vivo and imaginal exposure. Opriş et al. (2012) reported a non-significant effect size in favour of in vivo and imaginal exposure (d = 0.13, 95% CI [−0.11, 0.38] for three social phobia studies, suggesting that VRET and standard treatments had comparable efficacy. Kampmann, Emmelkamp, and Morina (2016) reported similar non-significant findings in favour of VR in comparison to empirically supported treatments across three studies, with g = −0.24, 95% CI [−0.71, 0.23]. A difference between these two meta-analyses was that Kampmann, Emmelkamp, and Morina (2016) restricted their analysis to ran- domised control trials and participants with diagnosed social anxiety disorder, whereas Opriş et al. (2012) did not require participants to have a clinical diagnosis and included studies with various meth- odological designs (e.g., non-random, quasi-random).
In each of these meta-analyses, researchers examined the efficacy of VRET for social anxiety by including it as a subcategory of a larger analysis. Within these subanalyses, the number of studies on social anxiety ranged from two to four, and the total number of participants ranged from 50 to
216. Moreover, the researchers included some small studies with low participant numbers. When com- pared to bigger studies, smaller studies often show larger and different treatment effects (Sterne, Gavaghan, & Egger, 2000). Further, small studies are regularly selected for publication because of their statistically significant results (Sterne et al., 2000). This phenomenon contributes to publication bias (publishing only favourable results) and can therefore affect the generalisability of effect sizes in meta-analysis (Sterne et al., 2000). Although Kampmann, Emmelkamp, and Morina (2016) acknowl- edged the issue of publication bias in the report of their meta-analysis, they could not examine its influence on effect sizes in their VRET analysis because of the low number of studies included.
Individual studies considered in the reviewed meta-analyses investigated the efficacy of VRET for social anxiety by assessing participants’ social anxiety symptomatology with various outcome mea- sures, such as the Liebowitz Social Anxiety Scale (Liebowitz, 1987), which has high levels of reliability and validity (Heimberg et al., 1999), and behavioural measures, such as total time speaking, which have face validity.
In sum, previous meta-analytic studies of the effects of VRET for social anxiety have had two main deficiencies: a very low number of studies and a lack of evaluation of publication bias. While a meta-analysis only requires a minimum of two studies (Valentine, Pigott, & Rothstein, 2010), increas- ing this number tends to enhance the generalisability of results (Schmidt & Hunter, 2014).
Aims and Hypotheses of the Present Study
The overall objective of the present study was to examine, through two meta-analyses, the efficacy of VRET for reducing symptoms of social anxiety. We aimed to improve on prior analyses by employing a more methodologically rigorous design. We further aimed to consider the impact of publication bias in order to improve the precision of effect size estimates. First, we assessed the efficacy of VRET com- pared to a waitlist control. Second, we compared the efficacy of VRET to the standard treatments of in vivo or imaginal exposure. We tested the following hypotheses in two separate meta-analyses:
H1: Virtual reality exposure therapy would demonstrate greater efficacy in reducing social anxiety than a waitlist control condition.
H2: The standard treatments of in vivo or imaginal exposure would demonstrate greater efficacy in reducing social anxiety when compared to virtual reality exposure therapy.
We searched the electronic databases PubMed, EBSCOhost, Proquest Central, PsychINFO and Proquest Dissertations and Theses in July 2017 for published and unpublished studies. We searched the databases using Boolean operators to link the search terms and phrases ‘virtual reality exposure therapy’ or ‘VRET’ or ‘virtual reality therapy’ or ‘VRT’ and ‘social anxiety’ or ‘social phobia’. We sought studies in Google Scholar by searching in the title using the exact phrases ‘virtual reality expos- ure therapy’ or ‘virtual reality therapy’, ‘VRT’, or ‘VRET’, and at least one of the terms ‘social’, ‘anxiety’, or ‘phobia’. There were no date limits set on the search. Articles had to be in English. We sought further studies from reference lists of retrieved articles. We wrote to authors of studies included in the meta-analysis to enquire after unpublished studies investigating the effects of VRET on social anxiety. We evaluated studies for inclusion by systematically analysing the title and abstract and then the full text. Figure 1 provides a summary of the search process.
Inclusion Criteria and Evaluation Process
Studies had to meet the following criteria for inclusion in the meta-analysis: (1) The study must be a well-controlled trial with random assignment, quasi-random assignment or participant matching pro- cedures that minimise bias. (2) The study must not use the same sample as another study. (3) The study report must be in English. (4) The study must have a VRET condition and at least one compari- son condition, which is a waitlist or an exposure treatment using in vivo or imaginal exposure. (5) Comparison treatments must not include VRET. (6) The article must provide treatment assessment data for social anxiety symptomatology, such as appropriate reporting of means and standard devia- tions. (7) Social anxiety must be the main target of the intervention.
We excluded measures not relating directly to social anxiety, such as depression, general anxiety, and quality-of-life scales. Excluding these measures maintained the focus on social anxiety. We used outcome-measure totals rather than subscale values, if researchers reported both. Two studies used the Self-Statements During Public Speaking (Hofmann & DiBartolo, 2000) scale, which contains positive and negative subscales. The negative subscale is a direct measure of social anxiety, shows more sensitivity to change than the positive scale, is more highly correlated with social anxiety, and is better able to differentiate between individuals with and without social anxiety (Hofmann & DiBartolo, 2000). As a result, we included only the negative subscale in the analysis.
The time of final comparison for each of the two meta-analysis was the latest measured time point during which participants remained in their originally allocated conditions, unless more than half the participants were lost by that time point. If available, we used carry-forward intention-to-treat (ITT) data because it offers a more conservative estimate of treatment outcomes (Gupta, 2011). In ITT, the pretreatment scores of participants who do not complete the postassessment are carried forward to serve as their post-intervention scores.
The authors Heuett and Heuett (2011) informed us, upon our contacting them, that they randomly assigned participants in their study to treatment conditions but not to the waitlist. The waitlist was comprised of individuals who filled out pretest forms incorrectly or were absent during the baseline assessment. There was evident systematic bias in the participant assignment to this condition. Therefore, we excluded the waitlist conditions from the meta-analysis. Furthermore, the data reported for two of the outcome measures at pretreatment in Heuett and Heuett’s imaginal exposure condition were implausible in an absolute sense and inconsistent with the other conditions, likely due to printing errors in the article. Therefore, we excluded from the analysis the results reported for the Willingness to Communicate scale and the Self-Perceived Communication Competence scale.
The results reported in Safir, Wallach, and Bar-Zvi (2012) are the follow-up assessment for Wallach et al. (2009). We used the 1-year data in Safir et al. (2012) for the comparison of VRET and standard treatments. Since the researchers did not assess waitlist at 1 year, we used the 12-week time point for the VRET and waitlist comparison.
We included two studies that used quasi-random assignment to condition and one study that used matching of participants prior to assignment to condition. Wallach et al. (2009) allocated participants to conditions by order of arrival, which is not true random assignment (Torgerson & Torgerson, 2008). Further, Wallach et al. (2009) used weighted assignment later in the study due to sample attrition, which allowed the researchers to maintain groups of equal size. Harris, Kemmerling, and North (2002) allocated four counsellor-referred participants straight to the waitlist and randomly assigned the remaining participants. Klinger et al. (2005) matched participants on key variables (e.g., age, gender) before assignment to conditions. Despite the lack of random assignment, we con- sidered this a well-controlled trial and included it in the meta-analysis.
Study Coding and Intercoder Agreement
Two of us jointly coded the following information for each study: publication characteristics (author and year of publication); age of participants; nature of the comparison group (treatment with exposure or waitlist); nature of participant assignment; outcome measures for assessing social anxiety symp- toms; time from baseline to final comparison of conditions; number of treatment sessions; study results (sample size, pre- and postassessment means and standard deviations); and the effect direction (positive or negative).
The third author independently checked the coding by randomly selecting four studies, which included 25 lines of data (out of a total of 50 lines) and 275 entries. For continuous data entries, we considered an agreement to be a variance of anything less than 5% of the original coded value. The agreement rate was 96%. Where there were disagreements, we made final decisions by consensus.
Statistical Procedure and Data Analysis
We calculated effect sizes using the coded values of the included studies, such as pre- and postassess- ment means and standard deviations for conditions. We used Hedges’ g, which is closely related to Cohen’s (1988) d, as the unbiased estimate of effect size. We used a random-effects model in the ana- lysis to allow for the possibility that effect sizes between studies differ (Borenstein, Hedges, Higgins, & Rothstein, 2010). The Q-value and I2 assessed heterogeneity across studies. While the Q-value is a sig- nificance test, I2 reports what percentage of total variability across studies in meta-analysis is due to between-study variability rather than to chance. Higgins and Thompson (2002) suggested tentative values of I2 in which 30% is mild, and exceeding 50% is large. A 95% confidence interval and a p value were computed for each model. We assessed the impact of publication bias using Orwin’s (1983) failsafe N, Duvall and Tweedie’s (1998) trim and fill method, and by viewing funnel plots. Negative values of g suggested results favoured standard treatment efficacy, whereas positive values indicated results favoured VRET efficacy. We conducted all analyses using Comprehensive Meta-Analysis (Version 3.3.070, 2014).
We first performed analyses with all studies relevant to each analysis. However, not every study used random assignment. Lacking randomisation makes these studies more susceptible to confound- ing bias (see Faber, Ravaud, Riveros, Perrodeau, & Dechartres, 2016). Randomised control trials are considered the gold standard in research design and provide the best evidence for assessing the efficacy of treatment (Faraoni & Schaefer, 2016). Further, randomised trials increase the statistical power and precision of estimated effects in meta-analysis (Wetterslev, Thorlund, Brok, & Gluud, 2008). So, we conducted a second set of analyses including only trials using random assignment.
The search strategy resulted in nine relevant studies, with a total of 573 participants. The meta-analysis data file can be obtained by contacting the corresponding author. Table 1 provides a summary of the key characteristics of the included studies. Figure 2 shows: (1) the studies used in the comparison of VRET and waitlist control conditions analysis, and (2) the studies used in the comparison of VRET and in-vivo or imaginal exposure therapy analysis and a forest plot of the effect sizes.
Emily Carla,⁎, Aliza T. Steina, Andrew Levihn-Coonb,c, Jamie R. Pogued, Barbara Rothbaume,
Paul Emmelkampf, Gordon J.G. Asmundsong, Per Carlbringh,i, Mark B. Powersa,d
a Department of Psychology, The University of Texas at Austin, Austin, TX, United States
b San Francisco Veterans Aﬀairs Medical Center, San Francisco, CA, United States
c Northern California Institute for Research and Education, San Francisco, CA, United States
d Baylor University Medical Center, Dallas, TX, United States
e Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, United States f Department of Clinical Psychology, University of Amsterdam, Amsterdam, The Netherlands g Department of Psychology, University of Regina, Regina, SK, Canada
h Department of Psychology, Stockholm University, Stockholm, Sweden
i University of Southern Denmark, Odense, Denmark
A R T I C L E I N F O
Meta-Analysis Virtual reality VR
Virtual reality exposure therapy VRET
A B S T R A C T
Trials of virtual reality exposure therapy (VRET) for anxiety-related disorders have proliferated in number and diversity since our previous meta-analysis that examined 13 total trials, most of which were for speciﬁc phobias (Powers & Emmelkamp, 2008). Since then, new trials have compared VRET to more diverse anxiety and related disorders including social anxiety disorder (SAD), posttraumatic stress disorder (PTSD), and panic disorder (PD) with and without agoraphobia. With the availability of this data, it is imperative to re-examine the eﬃcacy of VRET for anxiety. A literature search for randomized controlled trials of VRET versus control or in vivo exposure yielded 30 studies with 1057 participants. Fourteen studies tested VRET for speciﬁc phobias, 8 for SAD or performance anxiety, 5 for PTSD, and 3 for PD. A random eﬀects analysis estimated a large eﬀect size for VRET versus waitlist (g = 0.90) and a medium to large eﬀect size for VRET versus psychological placebo conditions (g = 0.78). A comparison of VRET and in vivo conditions did not show signiﬁcantly diﬀerent eﬀect sizes (g = −0.07). These ﬁndings were relatively consistent across disorders. A meta-regression analysis revealed that larger sample sizes were associated with lower eﬀect sizes in VRET versus control comparisons (β = −0.007, p < 0.05). These results indicate that VRET is an eﬀective and equal medium for exposure therapy.
Estudios clínicos sobre HRV Biofeedback
Applied Psychophysiology and Biofeedback
Marcos Economides · Paul Lehrer · Kristian Ranta · Albert Nazander · Outi Hilgert · Anu Raevuori · Richard Gevirtz · Inna Khazan · Valerie L. Forman‐Hoffman
© The Author(s) 2020
A rise in the prevalence of depression underscores the need for accessible and effective interventions. The objectives of this study were to determine if the addition of a treatment component showing promise in treating depression, heart rate variability-biofeedback (HRV-B), to our original smartphone-based, 8-week digital intervention was feasible and whether patients in the HRV-B (“enhanced”) intervention were more likely to experience clinically significant improvements in depressive symptoms than patients in our original (“standard”) intervention. We used a quasi-experimental, non-equivalent (matched) groups design to compare changes in symptoms of depression in the enhanced group (n = 48) to historical out- come data from the standard group (n = 48). Patients in the enhanced group completed a total average of 3.86 h of HRV-B practice across 25.8 sessions, and were more likely to report a clinically significant improvement in depressive symptom score post-intervention than participants in the standard group, even after adjusting for differences in demographics and engagement between groups (adjusted OR 3.44, 95% CI [1.28–9.26], P = .015). Our findings suggest that adding HRV-B to an app-based, smartphone-delivered, remote intervention for depression is feasible and may enhance treatment outcomes.
Clin Psychopharmacol Neurosci. 2019 Mar; 17(2): 222–232.
Published online 2019 Apr 30. doi: 10.9758/cpn.2019.17.2.222
I-Mei Lin,1,* Sheng-Yu Fan,,* Cheng-Fang Yen, Yi-Chun Yeh, Tze-Chun Tang, Mei-Feng Huang, Tai-Ling Liu, Peng-Wei Wang, Huang-Chi Lin, Hsin-Yi Tsai, and Yu-Che Tsai» src=»blob:https://www.psychosomatik.com/61724f14-b840-4c3c-bf1c-de47cbec0d0e» alt=»corresponding author» border=»0″ class=»Apple-web-attachment Singleton» style=»width: 0.0729in; height: 0.0937in; opacity: 1;»>
Autonomic imbalance is considered a psychopathological mechanism underlying major depressive disorder (MDD). Heart rate variability (HRV) is an index for autonomic activation. Poor sleep quality is common among patients with MDD. HRV biofeedback (BF) has been used for regulating autonomic balance among patients with physical illness and mental disorders. The purpose of present study was to examine the effects of HRV-BF on depressive symptoms, sleep quality, pre-sleep arousal, and HRV indices, in patients with MDD and insomnia.
In this case-controlled study, patients with MDD and Pittsburgh Sleep Quality Index (PSQI) score higher than 6 were recruited. The HRV-BF group received weekly 60-minute protocol for 6 weeks, and the control group who have matched the age and sex received medical care only. All participants were assessed on Beck Depression Inventory-II, Back Anxiety Inventory, PSQI, and Pre-Sleep Arousal Scale. Breathing rates and electrocardiography were also performed under resting state at pre-testing, and post-testing conditions and for the HRV-BF group, also at 1-month follow-up.
In the HRV-BF group, symptoms of depression and anxiety, sleep quality, and pre-sleep arousal were significantly improved, and increased HRV indices, compared with the control group. Moreover, in the HRV-BF group, significantly improved symptoms of depression and anxiety, decreased breathing rates, and increased HRV indices were detected at post-testing and at 1-month follow-up, compared with pre-testing values.
We performed a systematic and meta analytic review of heart rate variability biofeedback (HRVB) for various symptoms and human functioning. We analyzed all problems addressed by HRVB and all outcome measures in all studies, whether or not relevant to the studied population, among randomly controlled studies. Targets included various biological and psychological problems and issues with athletic, cognitive, and artistic performance. Our initial review yielded 1868 papers, from which 58 met inclusion criteria. A significant small to moderate effect size was found favoring HRVB, which does not differ from that of other effective treatments. With a small number of studies for each, HRVB has the largest effect sizes for anxiety, depression, anger and athletic/artistic performance and the smallest effect sizes on PTSD, sleep and quality of life. We found no significant differences for number of treatment sessions or weeks between pretest and post-test, whether the outcome measure was targeted to the population, or year of publication. Effect sizes are larger in comparison to inactive than active control conditions although significant for both. HRVB improves symptoms and and functioning in many areas, both in the normal and pathological ranges. It appears useful as a complementary treatment. Further research is needed to confirm its efficacy for particular applications.
Estudios medicos sobre transcranial direct current stimulation (tDCS)
Eman M. Khedr, MD, Ragaa H. Salama, MD, Mohamed Abdel Hameed, MD, …
First Published April 3, 2019
To explore the neuropsychological effects and levels of tau protein (TAU), amyloid β 1-42 (Aβ 1-42), and lipid peroxidase after 10 sessions of anodal transcranial direct current stimulation (tDCS) in patients with mild to moderate Alzheimer disease (AD). Patients and methods. A total of 46 consecutive patients with probable AD participated in this study. They were classified randomly into 2 equal groups: active versus sham. Each patient received 10 sessions of anodal tDCS over the left and right temporoparietal region for 20 minutes for each side with the cathode on the left arm. Patients were assessed using the Modified Mini Mental State Examination (MMMSE), clock drawing test, Montreal Cognitive Scale (MoCA), and the Cornell Scale for depression. Serum TAU, Aβ 1-42, and lipid peroxidase were measured before and after the 10th session. Results. There was a significant improvement in the total score of each cognitive rating scale (MMMSE, clock drawing test, and MoCA) in the real group, whereas no such change was observed in the sham group. The Cornell depression score improved significantly in both groups. There was a significant increase in serum Aβ 1-42 (P = .02) in the real but not in the sham group, with a significant Treatment condition × Time interaction (P = .009). There was no significant effect on tau or lipid peroxidase in either group but a significant positive correlation between changes of Aβ1-42 and MMMSE (P = .005) and MoCA (P= .02). Conclusion. The observed cognitive improvements were complemented by parallel changes in serum levels of Aβ 1-42.
Lais B. Razza
Adriano H. Moffa
Andre F. Carvalho
Colleen K. Loo
Andre Russowsky Brunoni
First published: 26 February 2020
Transcranial direct current stimulation (tDCS) has shown mixed results for depression treatment.
To perform a systematic review and meta‐analysis of trials using tDCS to improve depressive symptoms.
A systematic review was performed from the first date available to January 06, 2020 in PubMed, EMBASE, Cochrane Library, and additional sources. We included randomized, sham‐controlled clinical trials (RCTs) enrolling participants with an acute depressive episode and compared the efficacy of active versus sham tDCS, including association with other interventions. The primary outcome was the Hedges’ g for continuous depression scores; secondary outcomes included odds ratios (ORs) and number needed to treat (NNT) for response, remission, and acceptability. Random effects models were employed. Sources of heterogeneity were explored via metaregression, sensitivity analyses, subgroup analyses, and bias assessment.
We included 23 RCTs (25 datasets, 1,092 participants), most (57%) presenting a low risk of bias. Active tDCS was superior to sham regarding endpoint depression scores (k = 25, g = 0.46, 95% confidence interval [CI]: 0.22–0.70), and also achieved superior response (k = 18, 33.3% vs. 16.56%, OR = 2.28 [1.52–3.42], NNT = 6) and remission (k = 18, 19.12% vs. 9.78%, OR = 2.12 [1.42–3.16], NNT = 10.7) rates. Moreover, active tDCS was as acceptable as sham. No risk of publication bias was identified. Cumulative meta‐analysis showed that effect sizes are basically unchanged since total sample reached 439 participants.
TDCS is modestly effective in treating depressive episodes. Further well‐designed, large‐scale RCTs are warranted.
Volumes 17–18, November–December 2019, Pages 17-22
Mayank V.Jogab Danny J.J.Wangb Katherine L.Narrac
- TDCS of the left dorsolateral prefrontal cortex can reduce depressive symptoms.
- TDCS may be less suited for treatment-resistant depression.
- Combining tDCS with pharmaco- or psychotherapies may enhance therapeutic outcomes.
- Optimizing tDCS parameters to individual patients can improve physiological response.
Transcranial direct current stimulation (tDCS) is a low intensity neuromodulation technique shown to elicit therapeutic effects in a number of neuropsychological conditions. Independent randomized sham-controlled trials and meta- and mega-analyses demonstrate that tDCS targeted to the left dorsolateral prefrontal cortex can produce a clinically meaningful response in patients with major depressive disorder (MDD), but effects are small to moderate in size. However, the heterogeneous presentation, and the neurobiology underlying particular features of depression suggest clinical outcomes might benefit from empirically informed patient selection. In this review, we summarize the status of tDCS research in MDD with focus on the clinical, biological, and intrinsic and extrinsic factors shown to enhance or predict antidepressant response. We also discuss research strategies for optimizing tDCS to improve patient-specific clinical outcomes. TDCS appears suited for both bipolar and unipolar depression, but is less effective in treatment resistant depression. TDCS may also better target core aspects of depressed mood over vegetative symptoms, while pretreatment patient characteristics might inform subsequent response. Peripheral blood markers of gene and immune system function have not yet proven useful as predictors or correlates of tDCS response. Though further research is needed, several lines of evidence suggest that tDCS administered in combination with pharmacological and cognitive behavioral interventions can improve outcomes. Tailoring stimulation to the functional and structural anatomy and/or connectivity of individual patients can maximize physiological response in targeted networks, which in turn could translate to therapeutic benefits.
Estudios clínicos sobre EMDR
Patricia Novo Navarroa,b,c, Ramón Landin-Romerod,e,f,g, Rocio Guardiola-Wanden-Bergheb,c, Ana Moreno-Alcázarc,d, Alicia Valiente-Gómezc,d, Walter Lupoh, Francisca Garcíai, Isabel Fernándezj, Víctor Pérezb,c
y Benedikt L. Amannc,d,∗
Eye movement desensitization and reprocessing (EMDR) is a relatively new psychot- herapy that has gradually gained popularity for the treatment of post-traumatic stress disorder. In the present work, the standardised EMDR protocol is introduced, along with current hypot- heses of its mechanism of action, as well as a critical review of the available literature on its clinical effectiveness in adult post-traumatic stress disorder. A systematic review of the published literature was performed using PubMed and PsycINFO databases with the keywords «eye movement desensitization and reprocessing» and «post-traumatic stress disorder» and its abbreviations «EMDR» and «PTSD». Fifteen randomised controlled trials of good methodologi- cal quality were selected. These studies compared EMDR with unspecific interventions, waiting lists, or specific therapies. Overall, the results of these studies suggest that EMDR is a useful, evidence-based tool for the treatment of post-traumatic stress disorder, in line with recent recommendations from different international health organisations.
© 2016 SEP y SEPB. Published by Elsevier España, S.L.U. All rights reserved.
- de Jongh, Ad
- Amann, Benedikt L.
- Hofmann, Arne
- Farrell, Derek
- Lee, Christopher W.
Journal of EMDR Practice and Research
Vol 13Issue 4
Given that 2019 marks the 30th anniversary of eye movement desensitization and reprocessing (EMDR) therapy, the purpose of this article is to summarize the current empirical evidence in support of EMDR therapy as an effective treatment intervention for posttraumatic stress disorder (PTSD). Currently, there are more than 30 randomized controlled trials (RCT) demonstrating the effectiveness in patients with this debilitating mental health condition, thus providing a robust evidence base for EMDR therapy as a first-choice treatment for PTSD. Results from several meta-analyses further suggest that EMDR therapy is equally effective as its most important trauma-focused comparator, that is, trauma-focused cognitive behavioral therapy, albeit there are indications from some studies that EMDR therapy might be more efficient and cost-effective. There is emerging evidence showing that EMDR treatment of patients with psychiatric disorders, such as psychosis, in which PTSD is comorbid, is also safe, effective, and efficacious. In addition to future well-crafted RCTs in areas such as combat-related PTSD and psychiatric disorders with comorbid PTSD, RCTs with PTSD as the primary diagnosis remain pivotal in further demonstrating EMDR therapy as a robust treatment intervention.
- Tesarz, Jonas
- Wicking, Manon
- Bernardy, Kathrin
- Seidler, Günter H.
Journal of EMDR Practice and Research Vol 13 Issue 4 DOI:
Chronic pain is the most common global cause of functional and quality of life limitations. Although there are many effective therapies for the treatment of acute pain, chronic pain is often unsatisfactory. Against this background, there is currently an urgent need to develop innovative therapies that enable more efficient pain relief. Psychosocial factors play an important role in the development and persistence of chronic pain. Especially in patients with high levels of emotional stress, significant anxiety, or relevant psychological comorbidity, classical pain therapy approaches often fail. This is in line with the results of recent pain research, which has shown that dysfunctions in emotion processing have a significant influence on the persistence of pain symptoms. The recognition that pain can become chronic through maladaptive emotional processing forms the pathophysiological basis for the application of eye movement desensitization and reprocessing (EMDR) in the treatment of chronic pain. In this sense, EMDR can be used as an established method for desensitizing and processing of emotional distress from trauma therapy specifically for processing emotional stress in patients with chronic pain. Against this background, it is not surprising that the implementation of EMDR for patients with chronic pain is expanding. However, the increasing clinical use of EMDR in the treatment of chronic pain has also led to a reputation to test the efficacy of EMDR in pain management through randomized clinical trials. In addition to numerous case control studies, there are now also six randomized controlled clinical trials available that demonstrate the efficacy and safety of EMDR in the treatment of different pain conditions. However, in order to overcome several methodological limitations, large multicenter studies are needed to confirm the results.
Marianne Littel* , Marcel A. van den Hout and Iris M. Engelhard
Clinical Psychology, Utrecht University, Utrecht, Netherlands
Eye movement desensitization and reprocessing (EMDR) is an effective treatment for posttraumatic stress disorder. During this treatment, patients recall traumatic memo- ries while making horizontal eye movements (EM). Studies have shown that EM not only desensitize negative memories but also positive memories and imagined events. Substance use behavior and craving are maintained by maladaptive memory associa- tions and visual imagery. Preliminary findings have indicated that these mental images can be desensitized by EMDR techniques. We conducted two proof-of-principle studies to investigate whether EM can reduce the sensory richness of substance-related mental representations and accompanying craving levels. We investigated the effects of EM on (1) vividness of food-related mental imagery and food craving in dieting and non-dieting students and (2) vividness of recent smoking-related memories and cigarette craving in daily smokers. In both experiments, participants recalled the images while making EM or keeping eyes stationary. Image vividness and emotionality, image-specific craving and general craving were measured before and after the intervention. As a behavioral outcome measure, participants in study 1 were offered a snack choice at the end of the experiment. Results of both experiments showed that image vividness and crav- ing increased in the control condition but remained stable or decreased after the EM intervention. EM additionally reduced image emotionality (experiment 2) and affected behavior (experiment 1): participants in the EM condition were more inclined to choose healthy over unhealthy snack options. In conclusion, these data suggest that EM can be used to reduce intensity of substance-related imagery and craving. Although long-term effects are yet to be demonstrated, the current studies suggest that EM might be a useful technique in addiction treatment.
Front. Psychiatry 7:14. doi: 10.3389/fpsyt.2016.00014
Hwallip Bae • Changwoo Han • Daeho Kim
Ó Springer Science+Business Media New York 2013
This case series introduces the desensitization of triggers and urge reprocessing (DeTUR), as a promising adjunctive therapy in addition to comprehensive treatment package for pathological gambling. This addiction protocol of eye movement desensiti- zation and reprocessing was delivered to four male inpatients admitted to a 10-week inpatient program for pathological gambling. The therapist gave three 60-min weekly sessions of the DeTUR using bilateral stimulation (horizontal eye movements or alterna- tive tactile stimuli) focusing on the hierarchy of triggering situations and the urge to initiate gambling behaviors. After treatment, self-reported gambling symptoms, depression, anx- iety, and impulsiveness were all improved, and all the participants reported satisfaction with the therapy. They were followed up for 6 months and all maintained their abstinence from gambling and their symptomatic improvements. Given the efficiency (i.e., brevity and efficacy) of the treatment, a controlled study to confirm the effects of the DeTUR on pathological gambling would be justified.
Open Access Original
Article DOI: 10.7759/cureus.3250
Review began 08/31/2018
Review ended 08/31/2018
Ali M. Khan 1 , Sabrina Dar 2 , Rizwan Ahmed 3 , Ramya Bachu 4 , Mahwish Adnan 5 , Vijaya Padma Kotapati 6
1. Psychiatry Resident, University of Texas Rio Grande Valley, Harlingen, Texas, USA 2. Psychiatry, Saint Elizabeth’s Medical Center, Boston, MA, USA 3. Psychiatry, Liaquat College, Karachi, PAK 4. Psychiatry, Northwell Zucker Hillside Hospital, New York, USA 5. Center for Addiction and Mental Health, University of Toronto, Toronto, CAN 6. Psychiatry, Manhattan Psychiatric Center, New York, USA
Corresponding author: Vijaya Padma Kotapati, firstname.lastname@example.org Disclosures can be found in Additional Information at the end of the article
Post-traumatic stress disorder (PTSD) is prevalent in children, adolescents and adults. It can occur alone or in comorbidity with other disorders. A broad range of psychotherapies such as cognitive behavioral therapy (CBT) and eye movement desensitization and reprocessing (EMDR) have been developed for the treatment of PTSD.
Through quantitative meta-analysis, we aimed to compare the efficacy of CBT and EMDR: (i) relieving the post-traumatic symptoms, and (ii) alleviating anxiety and depression, in patients with PTSD.
We systematically searched EMBASE, Medline and Cochrane central register of controlled trials (CENTRAL) for articles published between 1999 and December 2017. Randomized clinical trials (RCTs) that compare CBT and EMDR in PTSD patients were included for quantitative meta- analysis using RevMan Version 5.
Fourteen studies out of 714 were finally eligible. Meta-analysis of 11 studies (n = 547) showed that EMDR is better than CBT in reducing post-traumatic symptoms [SDM (95% CI) = -0.43 (- 0.73 – -0.12), p = 0.006]. However, meta-analysis of four studies (n = 186) at three-
month follow-up revealed no statistically significant difference [SDM (95% CI) = -0.21 (-0.50 – 0.08), p = 0.15]. The EMDR was also better than CBT in reducing anxiety [SDM (95% CI) = -0.71 (-1.21 – -0.21), p =0.005]. Unfortunately, there was no difference between CBT and EMDR in reducing depression [SDM (95% CI) = -0.21 (-0.44 – 0.02), p = 0.08].
The results of this meta-analysis suggested that EMDR is better than CBT in reducing post- traumatic symptoms and anxiety. However, there was no difference reported in reducing depression. Large population randomized trials with longer follow-up are recommended to build conclusive evidence.